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Abstract 
 
The development of molecularly targeted anticancer agents relies on large panels of 
tumor-specific preclinical models closely recapitulating the molecular heterogeneity 
observed in patients. Here we describe the mutational and gene expression analyses of 
151 colorectal cancer (CRC) cell lines. We find that the whole spectrum of CRC molecular 
and transcriptional subtypes, previously defined in patients, is represented in this cell line 
compendium. Transcriptional outlier analysis identifies RAS/BRAF wild type cells, resistant 
to EGFR blockade, functionally and pharmacologically addicted to kinase genes including 
ALK, FGFR2, NTRK1/2 and RET. The same genes are present as expression outliers in 
CRC patient samples. Genomic rearrangements (translocations) involving the ALK and 
NTRK1 genes are associated with overexpression of the corresponding proteins in CRC 
specimens. The approach described here can be used to pinpoint CRCs with exquisite 
dependencies to individual kinases for which clinically approved drugs are already 
available. 
 
 
Introduction 
 
Knowledge of tumor biology and the development of new anticancer agents depend on 
robust preclinical model systems that reflect the genomic heterogeneity of human cancers 
and for which detailed genetic and pharmacologic annotations are available. Cell lines 
represent a mainstay to functionalize molecular data as they allow experimental 
manipulation, global and detailed mechanistic studies, and high-throughput applications1, 2, 
3, 4. Virtually all commonly used cancer cells were continuously grown in vitro for years, 
and decades have often passed since they were originally derived from patients. The in 
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vitro culture conditions used to propagate cancer cells are far from the histological 
landscape in which they originated. These considerations are often cited to question the 
relevance of cell lines as cancer models.  We further observe that, for a given cancer type, 
only few cell lines (<10) are employed in most preclinical studies. The evidence that 
cancer patients have heterogeneous genetic features implies that a large number of 
lineage-specific cell lines is needed to capture the diversity observed in the clinic. 
Furthermore, cells commonly used to model a tumor type may not represent the patients 
that they intend to recapitulate. For instance, colorectal cancer (CRC) cell lines ordinarily 
used in preclinical studies often display microsatellite instability (MSI). MSI colorectal 
tumors are found in 10-15% patients 5, but they show an indolent clinical behavior and are 
less prevalent in more advanced stages of the disease, accounting for less than 5% in the 
metastatic setting 6, 7. Consequently, MSI cell lines do not properly recapitulate the clinical 
setting in which targeted agents are most commonly administered to CRC patients.  
 
In addition to ‘genetic’ driven subtypes, tumor lineages can be subdivided based on their 
transcriptional profiles. Transcriptional profiling has been recently used to identify distinct 
CRC subtypes 8, 9, 10, 11, 12. The subtypes are associated with biological and clinical features 
such as cell of origin, microsatellite instability, prognosis and response to treatments. 
Whether the transcriptional subtypes are maintained in CRC cell models and how this 
knowledge can be used to discover novel pharmacogenetic relationships has not been 
explored.  To address these challenges we assembled and annotated a comprehensive 
collection of 151 human CRC cells.  
Please add a short paragraph (2-3 sentences) to summarize the main findings of your 
manuscript. Those must be in the present tense. 
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We find that the molecular heterogeneity (oncogenic mutations and transcriptional 
subtypes) previously defined in CRC patients, is maintained in colorectal cancer cells. 
Individual lines can be stratified as responders or non-responders to EGFR blockade on 
the basis of clinically validated biomarkers. Transcriptional outlier analysis identifies CRC 
cells, resistant to EGFR blockade, pharmacologically addicted to kinase genes including 
ALK, FGFR2, NTRK1/2 and RET.  
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Results 
 
Genetic and transcriptional profiling of CRC cells 
 
A collection of 152 CRC cell lines was initially genotyped at ten different microsatellite loci 
(STR profile) to unequivocally define their genetic identities (Supplementary Data 1). This 
analysis revealed that a few cell lines, previously thought to be unrelated, were derived 
from the same individual (Supplementary Data 1). Global mRNA expression profiling was 
carried out on the entire cell bank and TiGER (tissue-specific gene expression database)13 
was exploited to perform a “tissue of origin” analysis (Supplementary Fig. 1a). The 
analysis revealed a probable non-intestinal origin for one line, COLO741, found to express 
skin-specific genes, including Tyrosinase (Supplementary Fig. 1b,c).  This, together with 
the lack of expression of the neuroendocrine markers CHGA, SYP, ENO2, ACPP and 
NCAM1, suggested that these cells are not derived from a CRC nor from a 
neuroendocrine tumor, but rather from a melanoma. For this reason, COLO741 cells were 
withdrawn from further analyses. HuTu80 cells displayed a small intestine-like signature 
(Supplementary Fig. 1d) and were included in subsequent analyses due to their intestinal 
origin. Gene expression-based hierarchical clustering revealed that cell lines with identical 
genetic background consistently clustered together (Fig. 1), indicating that the genotype 
maintained strong control over the transcriptome. The only exception was the 
COGA5/COGA5L pair; these lines were derived respectively from the primary tumor and a 
lymph node metastasis of the same patient 14. 
 
The 151 CRC cell line collection was then assessed for the occurrence of microsatellite 
instability (MSI). MSI was detected in 63/151 cases (42%) (Supplementary Data 1). It has 
been previously noted that a higher than expected fraction of CRC cell lines are MSI, 
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conceivably because MSI tumors can be more easily propagated in vitro 15. We also 
observed that the rare hypermutator/MSI-negative subgroup, identified in about 2% of 
CRC cases, is represented by three lines, HT115, HCC2998 and HT55 16.  
 
The mutational status of KRAS, NRAS, BRAF, and PIK3CA was next assessed as these 
genes are implicated in the response of CRC to EGFR targeted therapies and are often 
ascertained in the clinic (Supplementary Data 1). KRAS, NRAS and BRAF mutations were 
mutually exclusive and were present in 47%, 0.7% and 18% of the lines, respectively. 
PIK3CA mutations and PTEN status were detected in 18% and 14% of the cells, 
respectively, and occurred together with KRAS and BRAF at rates comparable to those 
previously reported17, 18, 19 (Supplementary Data 1). Overall, the complexity reached in this 
compendium effectively reflects the genetic heterogeneity recognized in sporadic CRCs. 
 
Sensitivity to cetuximab is an intrinsic trait of CRC cells 
 
The anti-EGFR monoclonal antibodies cetuximab or panitumumab are approved to treat 
metastatic CRC (mCRC) but achieve less than 10% objective response rates in 
unselected CRC patients when given in monotherapy 20. Clinical benefit to EGFR blockade 
is confined to 25% of cases carrying tumors wild-type for KRAS, NRAS and BRAF 21. To 
assess whether CRC lines recapitulated the above pharmacogenetic relationships, we 
determined sensitivity to cetuximab in the entire cell collection over a wide range of drug 
concentrations (Fig. 2, Supplementary Fig. 2 and Supplementary Data 1). Ten RAS/BRAF 
wild-type cell lines (7% of the entire collection or 20% of RAS/BRAF wild-type cells) were 
highly susceptible to cetuximab inhibition (Fig. 2, Supplementary Fig. 2a). Pharmacological 
parameters such as the area under the curve (AUC) or the percentage of cell growth 
inhibition at a clinically relevant drug concentration of 10 µg/ml 22 closely paralleled the 
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response rates observed in patients 20, 21(Supplementary Fig. 3a). Cells classified as 
sensitive died upon anti-EGFR treatment (Supplementary Fig. 3 b,c,d), while partially 
sensitive cells were mainly growth impaired (Supplementary Fig. 3 e). As observed in the 
clinical setting, KRAS, BRAF or NRAS mutations conferred complete resistance to EGFR 
blockade in CRC cells (Fisher exact text p value<0.001) (Fig. 2).  
 
CRC molecular subtypes are maintained in cell lines 
 
Colorectal tumors can be classified in up to six unique subtypes with diverse clinical 
features according to the genes they express 8, 9, 10, 11, 12. To what extent the transcriptional 
subtypes are cell-intrinsic or depend upon the microenvironment is unclear. Expression 
profiles were therefore used to assign each cell line to a molecular subtype 8, 9, 10, 11, 12 by 
the Nearest Template Prediction (NTP) algorithm, which also estimates the classification 
false discovery rate (FDR) 23. Each of the five classifiers was able to assign (FDR < 0.2) 
the large majority of the cell lines to a subtype. Classifications of cell lines according to the 
five systems, together with the respective FDRs, are reported in Supplementary Data 2. 
Significant overlaps were detected among distinct classifiers. We found that the CRC-
assigner (CRCA) classification system established by Sadanandam and colleagues12 
shared the highest overlap with all other classifiers (Supplementary Fig. 4a). It was 
therefore considered as a reference for reconciling the five classifiers into a unified 
consensus (Supplementary Fig. 4b). 
 
Molecular and pharmacological associations, which previously emerged in CRC samples 
using the CRCA-based classification, were recapitulated in the cells collection (Fig. 3). MSI 
cells were significantly enriched in inflammatory and goblet subtypes (p-values: 0.0334 for 
inflammatory, 0.008 for goblet) and less prevalent in the Transit Amplifying (TA) and Stem 
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groups, which were instead mainly composed of microsatellite stable (MSS) cell lines (p-
value<0.0005). BRAF mutated cell lines clustered in the inflammatory subtype (p-value = 
0.0005), while RAS mutations were equally distributed among subgroups. Notably, 6 out of 
9 RAS/BRAF wild type cetuximab sensitive cells belonged to the TA subtype (p=0.038). 
Such enrichment is in line with data on CRC specimens 12 (Fig. 3). 
 
Outlier tyrosine kinases overexpressed in CRC cells To unveil actionable targets likely 
to be driver oncogenes in CRC, we carried out an outlier expression analysis focused on 
protein kinases 24, as the latter are frequently implicated in cancer and are ideally suited 
for therapeutic inhibition. Of 448 kinase genes expressed in the dataset 25, 32 (7.1%) 
displayed an outlier expression profile. A striking increase in the prevalence of outliers was 
observed in the tyrosine kinase (TK) subfamily (15 out of 74, 2.84x enrichment, 
hypergeometric p-value<0.0001). Of these 15 TKs, 9 were outliers only in RAS/BRAF wild-
type cells, and were therefore named «WT-specific». The enrichment for WT-specific 
outliers in the TK subgroup was significant (9 out of 15, 3.21x enrichment, hypergeometric 
p-value<0.0005). Interestingly, 8 out of the 9 WT-specific outlier TKs clustered in cell lines 
resistant to cetuximab. The list of WT-specific outliers’ genes comprises ALK, FER, 
FGFR2, KIT, NTRK1, NTRK2, PDGFRA and RET (Fig. 4a).  
 
Outlier kinase genes are therapeutic targets in CRC cells 
 
We next performed genetic and functional validation of the TK outliers. We decided to 
focus on TKs for which targeted agents are in clinical trial or are already approved for 
treatment, namely ALK, FGFR2, KIT, NTRK1, NTRK2, RET and PDGFRA. This analysis 
revealed that overexpression of NTRK1 and FGFR2 is associated to molecular alterations, 
such as gene translocation (NTRK1) or gene amplification (FGFR2) (Supplementary Figs 
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5,6), previously described in cellular models and in cancer patients 26, 27, 28, thus validating 
the experimental approach. The other tyrosine kinase outlier genes were not previously 
reported in CRC cells.  We detected an in-frame gene fusion event between exon 20 of 
ALK and exon 13 of EML4 in C10 cells (Fig.4b). Break-apart FISH, cDNA PCR and 
western blot analysis confirmed the EML4-ALK translocation in C10 cells (Fig.4c-e).  We 
reasoned that if the outlier kinase genes were causally implicated as oncogenic drivers, 
they should be functionally relevant in the corresponding cell models. We also postulated 
that the functional dependencies would be cell specific. To formally test these possibilities 
we used two complementary approaches: reverse genetics and pharmacological inhibition. 
Candidate-specific gene suppression was achieved with siRNA. In all cases reduced 
protein expression of the ‘outlier’ TK resulted in significant impairment of cell growth, which 
was often accompanied by downstream signaling inhibition and apoptosis (Fig. 4f; 
Supplementary Figs. 5-8).  
 
Pharmacological validation of the TK outliers was performed using the following kinase-
targeted drugs: CEP701 (TRK inhibitor), AZD4547 (FGFR2 inhibitor), crizotinib (ALK 
inhibitor), ponatinib (RET inhibitor) and imatinib and nilotinib (KIT and PDGFRA inhibitor). 
The drug inhibition profiles were cell specific and paralleled the expression profiles of 
individual TKs confirmed by RNAseq in the corresponding cell models (Fig. 4g-h, 5 and 
Supplementary Fig. 5-8). In two cases (KIT and PDGFRA) drug inhibition did not affect cell 
growth (Supplementary Fig. 8d,h). Nonetheless, in KIT overexpressing cells a reverse 
genetic experiment revealed functional dependency (Supplementary Fig. 8b,c).  
 
Translocation of ALK and NTRK1 genes in colorectal cancer samples  
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To establish the clinical relevance of the cell line-based findings, we assessed whether the 
outlier TKs might be identified in CRC specimens using the same methodology.  To this 
end we downloaded from cBbioPortal 29, 30 (http://www.cbioportal.org) the RNAseq 
expression Z-scores for 352 CRC tissue samples generated by the Cancer Genome Atlas 
(TCGA) network 5. The entire set of candidates described above, with the exception of 
KIT, was independently validated as RNA expression outliers in the TCGA CRC dataset 
(Fig. 6a).  As a further validation, we verified whether the ‘outlier’ strategy could lead to 
retrieval of TK candidates in archival CRC specimens for which RNA is typically not readily 
available. In this scenario, the most practical screening method should be capable of 
interrogating protein (rather than RNA) expression, on formalin-fixed paraffin embedded 
(FFPE) samples. As a proof of principle, we focused on NTRK1/Trk-A and ALK. An 
immunohistochemistry (IHC) based screen was applied to 742 CRC FFPE samples using 
a Trk-A (the protein encoded by NTRK1 gene) specific antibody. One Trk-A outlier sample 
was unequivocally identified (Fig. 6b,c). The IHC profile was followed by break-apart FISH 
analysis, which detected NTRK1 genetic rearrangement in the TrK-A positive sample (Fig. 
6d). Screening with and ALK specific antibody of 742 CRC FFPE retrieved a sample with 
high levels of the ALK protein (Fig.6e,f). In the same specimen, break-apart FISH 
highlighted a genetic translocation involving the EML4 gene (Fig. 6g). 
 
Discussion 
 
Human neoplasms are highly heterogeneous, and clinical evidence indicates that 
pharmacogenetic relationships often involve oncogenic events occurring at low 
prevalence. Accordingly, precision oncology depends on the ability to functionally 
interrogate preclinical models capturing the molecular heterogeneity observed in patients. 
While collections of cancer cells derived from multiple tumor types have been previously 
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described 1, 2, 4, comprehensive databases of cells derived from single tumor lineages are 
much less common 16, 31. To capture the clinical heterogeneity of CRCs, we assembled a 
collection of 151 cell lines. Notably, genetic finger printing and transcriptional profiling 
highlighted that several CRC lines previously thought to be unrelated are in fact derived 
from the same individual. This finding should be helpful in designing future studies and 
may facilitate the interpretation of previous analysis involving ‘redundant’ cell models.  
 
The clinical relevance of the cell database was confirmed by showing that common 
oncogenic events (KRAS, NRAS, BRAF, PIK3CA and PTEN alterations) are present in the 
collection at rates similar to those found in CRC patients.  Previous studies evaluated 
sensitivity to EGFR blockade (with the anti EGFR antibody cetuximab) in a fraction of the 
CRC lines described in this work 32. We found a strong concordance among 
measurements obtained in independent laboratories, indicating that sensitivity to EGFR 
inhibition is a stable phenotype of colorectal tumors. While the molecular determinants of 
EGFR sensitivity are presently unknown, our data suggest a prominent intrinsic (cell 
autonomous) component in colorectal tumors. We conclude that genetic and 
pharmacological profiling CRC lines can successfully nominate clinically relevant 
molecular determinants of response to targeted therapies.  
 
In addition to the mutation-based categories described above, CRC can be subdivided in 
up to 6 transcriptional subtypes with distinct molecular and clinical features 8, 9, 10, 11, 12, 
which we found to be robustly maintained in cells grown in vitro. This observation, along 
with the evidence that independent cell lines derived from the same patient consistently 
co-cluster transcriptionally, suggests that the transcriptional profile is stable and 
predominantly controlled by the genome in the absence of environmental inputs. These 
results further support the functional correspondence of CRC cell panel described here 
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with CRC specimens. Previous studies have also suggested that the transcriptional CRC 
subtypes may be associated with drug response. Cell models recapitulated the association 
between response to EGFR inhibitors and enrichment for the TA transcriptional class, 
which was identified in CRC clinical samples 12. Along this line, the classification of cells 
reported in our work will facilitate future screenings with chemical or RNA interference 
libraries aimed at identifying novel pharmacogenomic relationships in specific 
transcriptional subtypes. 
 
We previously reported that a subset of colorectal tumors, in which resistance to EGFR 
blockade occurs in a RAS/RAF wild type background, display overexpression of two 
tyrosine kinase genes, HER2 or MET 33, 34. In 41/151 lines, which were analyzed in this 
study, the mechanism of resistance to cetuximab is unaccounted for. We hypothesized 
that in some of these cells resistance might likewise be driven by overexpression of a 
kinase gene. We therefore employed an outlier analysis based on expression levels of TK 
genes to identify additional kinase (and therefore actionable) targets in the subset of WT 
RAS/BRAF CRC cells intrinsically resistant to EGFR therapies. 
 
Seven of the TKs retrieved by this approach (ALK, FGFR2, KIT, NTRK1, NTRK2, RET and 
PDGFRA) are the target of drugs undergoing clinical testing or approved. In some 
instances (FGFR2, ALK or NTRK1), overexpression of the TK gene was associated with 
amplification or translocation of the corresponding locus. The same genetic alterations 
have been previously reported in CRC cells and patients 26, 27, 28, thus validating our 
approach. Our data further suggest that overexpression of TK sustains primary resistance 
to EGFR blockade, and could be used to identify patients unlikely to respond to cetuximab 
or panitumumab. Of note, with the exception of RET and FGFR2, which coexisted in 
NCIH716 cells, outlier expression of TKs was mutually exclusive. 
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Our results have broad implications for the use of kinase inhibitors in CRCs and potentially 
other cancer types. First, companion diagnostic assays are essential to identify those 
(rare) patients with tumors bearing aberrantly expressed kinases. Since the molecular 
events leading to protein overexpression can be multiple (gene amplification, gene fusions 
and translocations with different partners and breakpoints), we propose that IHC should be 
better suited than other methods to serve this purpose. As a test case, we demonstrated 
the feasibility of this approach to identify CRC patients carrying overexpressed and 
genetically altered Trk-A and ALK kinases. Additional work is warranted to develop and 
validate IHC assays for the other outlier TK genes. Importantly, given the low prevalence 
of these outlier events, strategies aimed at concomitantly screen for multiple molecular 
alterations should be implemented. Eventually, it is likely that next-generation sequencing 
will become the most effective approach to detect molecularly deregulated kinase genes 
as it allows concomitant assessment of single nucleotide variants as well as a gene copy 
number alterations and translocations. 
 
Our results also highlight the relevance of clinical trials involving CRC patients carrying 
molecularly altered tyrosine kinase genes, which can be readily identified using FFPE 
specimens. Our data suggest that these patients are unlikely to benefit from anti EGFR 
antibodies but likely to profit from currently available drugs such as ALK and TRK 
inhibitors.  It is important to note that in some instances (i.e. KIT), blockade of the kinase 
activity with a specific kinase inhibitor did not impair growth, while TK suppression with 
siRNA revealed functional dependency and triggered apoptosis. This suggests that down 
regulation of the candidate protein, for example through specific antibodies, might be 
necessary in some instances. Our data further suggest that tyrosine kinase inhibitors 
effectively impair tumor growth in cell lines in which transcriptional deregulation is 
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accompanied by genetic activation of the kinase (TRK, ALK, FGFR2), but not in the cell 
lines where no genetic activation was identified (PDGFR, KIT). 
 
In conclusion our results describe a powerful preclinical resource capturing the 
heterogeneity of colorectal cancer patients, which can be used to define multidimensional 
information of clinical relevance and applicability.  
 
 
METHODS 
 
Cell lines and reagents 
A collection of 152 cell lines of intestinal origin was assembled from different worldwide 
cell line banks or academic laboratories as indicated in Supplementary Data 1. All cell 
lines were maintained in their original culturing conditions according with supplier 
guidelines. Cells were ordinarily supplemented with FBS at different concentrations, 2mM 
L-glutamine, antibiotics (100U/mL penicillin and 100 mg/mL streptomycin) and grown in a 
37°C and 5% CO2 air incubator. Cells were routinely screened for absence of Mycoplasma 
contamination using the Venor® GeM Classic kit (Minerva biolabs). The identity of each 
cell line was checked by Cell ID™ System and by Gene Print® 10 System (Promega), 
throught Short Tandem Repeats (STR) at 10 different loci (D5S818, D13S317, D7S820, 
D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin). Amplicons from 
multiplex PCRs were separated by capillary electrophoresis (3730 DNA Analyzer, Applied 
Biosystems) and analyzed using GeneMapperID software from Life 
Technologies.  Resulting cell line STR profiles were cross-compared and matched with the 
available STR from ATCC, DSMZ, JCRB, Korean Cell Line Bank, ECCAC, and CellBank 
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Australia repositories online databases. Results of the analyzed loci for each cell line are 
provided in Supplementary Data 1.  
Cetuximab was obtained from the Pharmacy at Niguarda Ca’ Granda Hospital in Milan, 
Italy; Crizotinib, AZ4547, imatinib, ponatinib and nilotinib were purchased from Selleck 
Chemicals. CEP701 was purchased from Sigma Aldrich. 
 
DNA analysis  
Genomic DNA samples were extracted by Wizard® SV Genomic DNA Purification System 
(Promega). The MSI status has been evaluated by mean of MSI Analysis System kit 
(Promega). The analysis requires a multiplex amplification of seven markers including five 
mononucleotide repeat markers (BAT-25, BAT-26, NR-21, NR-24 and MONO-27) and two 
pentanucleotide repeat markers (Penta C and Penta D). The products were analyzed by 
capillary electrophoresis in a single injection (3730 DNA Analyzer, ABI capillary 
electrophoresis system (Applied Biosystems). The results were analyzed using 
GeneMarker V2.2.0 software. As cell lines do not have a corresponding normal tissue 
available for comparison, their profile has been analyzed with an MSS cell line of control, 
K562. Samples with instability in one, two or more markers (mononucleotide repeat) are 
defined as MS-instable (MSI). Samples with no detectable alterations are MS-stable 
(MSS). The same samples of genomic DNAs were used for PCR amplification to check 16 
hot spot CRC mutations in all cells (reported in Supplementary Data 1). The mutational 
status of KRAS (exons 2, 3, 4), NRAS (exons 2, 3), HRAS (exons 2 and 3), BRAF (exon 
15) and PIK3CA (exons 9 and 20) was determined by Sanger sequencing (primers’ 
sequences are listed in Supplementary Data 3).  
 
RNA extraction and gene expression profiling 
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RNA was extracted using miRNeasy Mini Kit (Qiagen), according to the manufacturer’s 
protocol. The quantification and quality analysis of RNA was performed on a Bioanalyzer 
2100 (Agilent), using RNA 6000 nano Kit (Agilent). Synthesis of cDNA and biotinylated 
cRNA was performed using the IlluminaTotalPrep RNA Amplification Kit (Ambion), 
according to the manufacturer’s protocol using 500ng of total RNA. Quality assessment 
and quantification of cRNAs were performed with Agilent RNA kits on Bioanalyzer 2100. 
Hybridization of cRNAs (750 ng) was carried out using Illumina Human 48k gene chips 
(Human HT-12 V4 BeadChip). Array washing was performed using Illumina High Temp 
Wash Buffer for 10’ at 55°C, followed by staining using streptavidin-Cy3 dyes (Amersham 
Biosciences). Probe intensity data were obtained using the Illumina Genome Studio 
software (Genome Studio V2011.1). Raw data were Loess normalized with the Lumi R 
package and further processed with Excel software.. 
 
Tissue of origin analysis  
Thirty panels of genes with tissue-specific expression were retrieved from the TIGER 
portal13 (http://bioinfo.wilmer.jhu.edu/tiger/) and filtered to remove gene symbol 
redundancies. Similarly, to avoid probe redundancy in array data, when multiple probes 
matched the same gene we selected the one with the highest standard deviation. For the 
tissue of origin analysis, we assumed that the vast majority of the cell lines present in this 
dataset were of colorectal origin, while only a very small fraction could possibly derive from 
other tissues. Therefore, to increase sensitivity of the colon-specific gene panel, genes not 
expressed (L2S<9) in at least 50 of the 152 CRC cells were removed from the panel. To 
increase specificity of other tissue-specific gene panels, genes from these panels 
expressed (L2S>9) in more than three CRC cell lines (2%) were also removed. For each 
gene of a tissue-specific panel, the TIGER database provided an “EST Enrichment” (EE) 
score, proportional to the extent of tissue specificity. To give more weight to genes with 
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high EE score in the estimation of the tissue of origin, EE scores were squared and 
summed. Then, the squared EE score of each gene was divided by the sum, to obtain a 
“Scaled EE score” representing what fraction of the tissue specificity of the gene panel is 
brought by each individual gene. Finally, a “tissue score” was calculated for each gene 
panel by summing the products of gene expression and scaled EE score, and using the 
resulting value as exponential of 2 to obtain linear values.  
 
Unsupervised expression clustering 
After removing the COLO741 melanoma cell line from the dataset, we assessed global 
transcriptional correlations across the remaining 151 cell lines by unsupervised clustering 
A detection filter was applied to the 151 cell line dataset by requesting that the reported 
detection p-value reported in GSE59857 was zero in at least one of the 151 samples.  
After detection filtering, when multiple probes matched the same gene we selected the 
one with the highest standard deviation. This led to identification of 19,828 unique genes 
detected in at least one cell line. Before clustering,, we applied a further filter based on 
standard deviation (SD) across samples (SD of Log2 Signal > 0.8). We then employed the 
Log2 signal of 3,132 genes passing this filter for hierarchical clustering with maximum 
linkage based on Pearson correlation, using the GEDAS software 35.  
 
Drug proliferation assay 
CRC cell lines were seeded at different densities (2-4 x103 cells/well) in 100μl complete 
growth medium in 96-well plastic culture plates at day 0. The following day, serial dilutions 
of the indicated drugs were added to the cells in serum-free medium, while medium-only 
(in case of cetuximab) or DMSO-only (for all the other drugs) treated cells were included 
as controls. Plates were incubated at 37°C in 5% CO2 for 4 or 5 days, after which cell 
viability was assessed by measuring ATP content through Cell Titer-Glo® Luminescent 
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Cell Viability assay (Promega). Luminescence was measured by Perkin Elmer Victor X4. 
Based on cell viability after 4 days of treatment with clinical relevant concentration of 
10µg/ml of cetuximab and on the shape of the drug screening-cell response growth 
curves, CRC cells were defined sensitive when cell viability was ≤40% at 10μg/ml of 
cetuximab. We then calculated the area under the curve index (AUC) for each cell line of 
the panel and selected the threshold of AUC index ≥13000 based on the values of AUC 
obtained in the subgroup of sensitive cell line. The area under the concentration–inhibition 
curve (Index AUC) was computed using Excel 36. The “cetuximab effect arbitrary index” 
was calculated by subtracting the threshold value of 13000 from the AUC index of each 
cell line to highlight the subpopulation of sensitive cell lines (those with a negative index). 
 
Classification of CRC cell lines into intrinsic subtypes 
To classify cell lines into CRC subtypes according to previously published transcriptional 
classification systems, gene lists for the five classifiers were obtained from the 
supplementary information of the relevant publications. We then employed the NTP 
algorithm 23 on the 151 CRC lines expression dataset of 19,828 genes described above. 
NTP is a nearest neighbor classifier developed to classify samples with defined gene 
signatures also when generated in a different microarray platform, and to provide an 
estimate of classification robustness by computing false discovery rate and p-value. NTP 
analysis was conducted using the GenePattern Bioportal37 
(http://www.broadinstitute.org/cancer/software/genepattern/).  
For NTP implementation, we selected genes positively and specifically associated to one 
subtype. The CRC subtype classifiers were generated by different procedures. To perform 
reciprocal comparisons in an independent dataset, based on a different microarray 
platform, we had to adapt them to a common classification strategy. The thresholds for 
gene selection described below were chosen to remove genes with low class 
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discrimination power (to improve sensitivity and specificity) while at the same time 
maintaining a reasonable number of classifying genes (for the stability and platform 
independence of the classifier). 
De Sousa E Melo 9 and Sadanandam 12 gene signatures have originally been defined 
using the same approach, i.e. Significance Analysis of Microarrays 38followed by 
Prediction analysis for microarrays (PAM) 39, to build lists of genes positively or negatively 
associated to each molecular subtype. The extent and sign of association is represented 
by the PAM score. To select only genes with a strong positive association to one class, we 
associated each gene to the class corresponding to the maximum PAM value, and only if 
the difference between the maximum and second highest value was sufficiently high 
(greater than 0.1). 
Subtype signatures of the Marisa10 classifier were defined by filtering the list of 1108 
genes provided in Table S10 of their work, using the associated log fold changes and 
adjusted p-values for each gene in each of the six CRC subtypes. In particular, we 
assigned a gene to a class signature if two conditions were met: (i) its fold change in the 
class was the highest among its fold changes in all the classes; (ii) the adjusted p-value in 
the same class was the minimum between the adjusted p-values of all the other classes 
with a positive fold change. As done for De Sousa E Melo and Sadanandam classifiers, in 
order to select only genes with a strong association to a single subtype, we selected only 
those genes having a difference between the highest and second highest log fold change 
greater than 0.2. The Roepman 11 signatures were defined on the basis of positive genes 
provided in Table 2 of the original work. The Budinska 8 gene signatures were provided on 
Table 1 of the original work as metagenes, each with statistical assessment of differential 
expression across subtypes. Adaptation to NTP required two steps: (i) selection of the 
metagenes specifically upregulated in each subtype, and (ii) extraction of the lists of genes 
belonging to the selected metagenes. A metagene was associated with a subtype if it was 
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significantly upregulated in that subtype, had the highest positive fold change (Log2 ratio 
vs median) in that subtype and if the difference against the second highest subtype was 
greater than a log2 ratio of 0.2. Then, for each subtype, the lists of genes belonging to the 
specifically upregulated metagenes were merged to build the subtype signatures. To 
compare the results obtained by the five different classifiers employed, we computed 
hypergeometric tests performing a paired-sample enrichment analysis, with Bonferroni 
correction of the resulting p-values. Associations between CRC subtypes and MSI status, 
BRAF/KRAS mutations and cetuximab sensitivity were evaluated by hypergeometric 
distribution analysis and Fisher’s exact test. 
 
Outlier expression analysis 
Outlier analysis was performed starting from the 151 CRC lines expression dataset. 
Expression of a gene in a cell line was considered outlier if it was both >5 standard 
deviations and >5-fold greater than its median expression across all cells. Kinase-
encoding genes were obtained from (http://kinase.com/human/kinome/) 25, after annotation 
with updated gene symbols and mapped on the detection-filtered expression dataset of 
19,828 unique genes described above. 
 
Gene copy number analysis 
CRC cell lines were trypsinized, washed with PBS and centrifuged; pellets were lysed and 
DNA was extracted as described above. Real time PCR was performed with 10 ng of DNA 
per single reaction using GoTaq QPCR Master Mix (Promega) with an ABI PRISM® 
7900HT apparatus (Applied Biosytems) (primers’ sequences are available on request). 
Gene copy numbers were normalized to a control diploid cell line, HCEC 40. 
 
siRNA screening 
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The siRNA targeting reagents were purchased from Dharmacon, as a SMARTpool of four 
distinct siRNA species targeting different sequences of the target transcript. Cell lines were 
grown and transfected with SMARTpool siRNAs using RNAiMAX (Invitrogen) transfection 
reagents following manufacturer’s instructions. Briefly RNAi screening conditions were as 
follow: on day one siRNA were distributed in each well of a 96-wellplate at final 
concentration of 20 nmol/L. Transfection reagents were diluted in OptiMEM and aliquoted 
at 10µl/well; after 20 minutes of incubation, 70µl of cells in media without antibiotics were 
added to each well. After five days, cell viability was estimated with a luminescent assay 
measuring cellular ATP levels with CellTiter-Glo® Luminescent Assay (Promega). Each 
plate included the following controls: mock control (transfection lipid only), AllStars 
(Qiagen) as negative control; Polo-like Kinase 1 (PLK1) (Dharmacon) as positive control41. 
siRNA sequences are listed in Supplementary Data 4.  
 
RNA seq 
Total RNA extracted from C10, KM12, SNU503, HCA24, CACO2, and, NCIH716 cells was 
processed for RNAseq analysis with Ion TotRNA Seq kit v2® following manifacturer’s 
instruction and sequenced with the Ion Proton™ System (Ambion - Life Technology). Each 
fastq file was realigned using Tophat2 v2.0.1142. Version hg19 of the genome was used 
and Gencode v19 as reference transcriptome database. The average value of the reads 
aligned by Tophat2 is 61%. The Fragments Per Kilobase of exon per Million fragments 
mapped (FPKM) was computed on the aligned reads using Cufflinks software v2.2.1 43. 
Moreover, each fastq file was analyzed by FusionMap software v 7.0.1.25 44 obtaining the 
list of fusion transcripts for each cell line. 
 
Immunohistochemistry. 
22 
 
FFPE colorectal cancer samples were available through the clinical database of Ospedale 
Niguarda and Istituto Nazionale Tumori Regina Elena. Additional CRC specimens tissue 
microarrays were purchased from Abcam (Cat. ab128127). Trk-A and ALK protein 
expression was evaluated by immunohistochemistry (IHC) performed on 3-4μm thick 
tissue sections, using specific antibodies In order to assess Trk-A expression, the 
monoclonal antibody (Clone ID EP1058Y, Epitomics, dilution 1:200), which recognizes the 
C-terminal portion of the protein  was used and the analysis was performed with the 
automated system BenchMark Ultra (Ventana Medical System, Inc., Roche) according to 
the manufacturer‘s instructions, with minimum modifications. Samples were incubated  
with the primary antibody for 1h  at 42°C, after which a chromogenic reaction was 
performed using the ultraView Universal Alkaline Phosphatase Red Detection kit (Ventana, 
Roche). ALK protein espression was detected using the anti ALK mouse  monoclonal 
antibody (clone 5A4)  which recognizes the intracellular region of ALK. The analysis was 
performed manually, using N-Histofine ALK Detection Kit, according to the manufacturer’s 
nstructions (Nichirei Biosciences Inc). Samples were incubated with the primary antibody 
for  30  min at room temperature and  DAB was used as chromogen. For both proteins, 
specimens were considered positive when the expression was strong and cytoplasmic and 
present in at least 10 % of cells. Healthy tissue, i.e, normal colon mucosa, was used as 
internal negative control. Images were captured with the AxiovisionLe software (Zeiss) 
using an Axio Zeiss Imager 2 microscope (Zeiss). 
 
 
Fluorescent in situ hybridisation analysis. 
Tissue sections and cyto-embedded cell lines for Fluorecent in situ hybridization (FISH) 
experiment were prepared according to the manufacturer‘s instructions of Histology FISH 
Accessory kit (Dako). For both types of samples (tissue and cell lines) the last steps before 
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hybridization were: dehydration in ethanol series (70%, 90%, 100%), 3 washes (5’ each) 
and air drying. To identify possible NTRK1 gene rearrangements, a dual colour break 
apart probe has been designed a contiguous of two BAC (Bacterial Artificial Chromosome) 
(http://genome.ucsc.) probes, RP11-349I17(1q23.1) and RP11-1038N13 (1q23.1), all 
together spanning an approximately 335 kb region encompassing the NTRK1 gene. A dual 
colour FISH analysis was performed using respectively: 10 μl mix- probe made up by 1.5μl 
BAC genomic probe RP11-349I17 (1q23.1) labelled in Spectrum Orange (Empire 
Genomics), 1,5 μl BAC genomic probe RP11-1038N13 (1q23.1) labelled in 
SpectrumGreen, and 7 μl LSI-WCP hybridisation buffer (Vysis) for each slide. In order to 
identify possible ALK gene rearrangements, an LSI ALK (2p23) Dual Color, Break Apart 
(Vysis) probe was used. Probes and target DNA of specimens were co-denatured in 
HYBRite System (DakoGlostrup) respectively at 75°C for 5 min using NTRK1 probe and at 
73° for 5 min for ALK probe, therefore hybridized overnight at 37° C. Slides were washed 
with post-hybridisation buffer (DakoGlostrup) at 73°C for 5 min and counterstained wit 4,6-
diamino-2phenylindole (DAPI II; Vysis, Downers Grove, IL. USA). Fluorescent in situ 
hybridisation signals were evaluated with a Zeiss Axioscope Imager. Z1 (Zeiss) equipped 
with single and triple band pass filters. Images for documentation were captured with CCD 
camera and processed using the MetaSystems Isis software. Samples were scored as 
positive either for NTRK1 or ALK gene‘s rearrangement when a split signal of the probes 
was observed, in at least 15% of 100 cells analyzed in 10 different fields. Healthy tissue, 
i.e, normal colon mucosa, was used as internal negative control. 
 
Western blotting analysis 
Prior to biochemical analysis, all cells were grown in their specific media 
supplemented with 10% FBS. Total cellular proteins were extracted by solubilizing 
the cells in EB buffer (50 mMHepes pH 7.4, 150 mMNaCl, 1% Triton X-100, 10% 
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glycerol, 5 mM EDTA, 2 mM EGTA; all reagents were from Sigma-Aldrich, except for 
Triton X-100 from Fluka) in the presence of 1 mM sodium orthovanadate, 100 mM 
sodium fluoride and a mixture of protease inhibitors. Extracts were clarified by 
centrifugation, normalized with the BCA Protein Assay Reagent kit (Thermo). 
Western blot detection was performed with enhanced chemiluminescence system 
(GE Healthcare) and peroxidase conjugated secondary antibodies (Amersham). The 
following primary antibodies were used for western blotting (all from Cell Signaling 
Technology, except where indicated): anti-FGFR2 (1:1000) ; anti-ALK; anti-Trk-A 
(Santa Cruz) (1:500); anti-Trk (Santa Cruz) (1:500); anti-cKIT (1:1000); anti-PDGFRA 
(1:1000); anti-phospho-p44/42 ERK (Thr202/Tyr204) (1:1000); anti-p44/42 ERK 
(1:1000); anti-phospho-MEK1/2 (Ser217/221) (1:1000); anti-MEK1/2 (1:1000); anti-
phospho AKT (Ser473) (1:1000); anti-AKT (1:1000); anti-PARP (1:1000); anti-actin 
(Santa Cruz) (1:3000); anti-vinculin (Millipore) (1:5000); anti-PTEN (1:1000). Anti-
RET antibody45 (1:500) was kindly provided by Prof. Massimo Santoro (Federico II, 
Naples). The full-length western blot membranes are shown in Supplementary Figs 
9–13. 
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Figure Legends 
 
Figure 1. Expression clustering of 151 CRC cell lines.  
Unsupervised hierarchical clustering of 151 CRC cell lines based on their global 
expression profile. Cell lines derived from the same individual (same STR) are highlighted 
by the same color. Names of cell lines with identical STR are reported below the 
dendrogram in the order by which they occur in the cluster, from left to right.  
 
Figure 2. Cetuximab screening on CRC cell lines. The indicated cell lines were treated 
with increasing concentrations of cetuximab for 4 days and cell viability was assessed by 
measuring ATP content. Bars represent an arbitrary index of cetuximab effect on each cell 
line as detailed in the methods. Cell lines sensitive to cetuximab treatment are shown with 
a negative index. Red bars represent KRAS altered lines; yellow bars indicate NRAS 
mutated cells; blue bars indicate genetic alterations affecting codon V600 of BRAF; black 
bars indicate RAS/BRAF wild type cells. NCIH630 cells are KRAS amplified 46.  
 
Figure 3. CRC transcriptional subtypes are maintained in cell lines. CRC cell lines are 
classified according to the “CRC-assigner” intrinsic transcriptional subtypes and the colon 
crypt location previously described12. MSI status, RAS/BRAF mutations and cetuximab 
sensitivity are indicated. FDR: false discovery rate. The Fig. includes only CRC cell lines 
that were assigned to a subtype with FDR < 0.2. Among cell lines sharing the same STR 
profile we selected,  the original cell line in case of groups of cells including also derived 
clones, and  in the absence of such information, the one classified with the highest 
confidence by the NTP algorithm..RASM: RAS mutated cells. BRAFM: BRAF mutated cells. 
Cetux: cetuximab.  
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Figure 4. Identification of outlier kinase genes in 151 CRC cell lines. (a) Scatter plot 
representation of transcriptional outlier kinases in 151 CRC cells. Colored circles represent 
outlier kinases with >5 standard deviations and >5-fold differential expression compared to 
median expression. Asterisk labels the KM12 family of cells: KM12, KKM12C, KM12SM, 
KM12L4. (b) RNA seq analysis unveiled an in-frame gene fusion event between exon 20 
of the ALK gene and the exon13 of the EML4 gene on chromosome 2 in the C10 CRC cell 
line. (c) Break apart FISH analysis of EML4-ALK in C10 cells shows clear separation of 
green (5’) and red (3’) signals corresponding to the ALK gene (original 63x magnification 
,scale bar=10µm). Scale bars, 10µm (d) PCR on the cDNA of C10 cells confirmed the 
EML4-ALK translocation (e) Western blot analysis confirmed overexpression of ALK 
protein in C10 cells, at a molecular weight compatible with an EML4-ALK genetic 
rearrangement. (f) RNAi knockdown of ALK inhibits cell proliferation of C10 cell line 
harboring the EML4-ALK fusion gene. C10 cells were analyzed by ATP lite proliferation 
assay 5 days after transfection with ALK-specific pooled siRNAs, scrambled siRNA, or 
transfection reagent (mock). Data are expressed as average ± s.d. of three independent 
experiments. si-RNA mediated downregulation of ALK levels were verified by western blot 
analysis. (g) C10 cells, resistant to the EGFR inhibitor cetuximab, are sensitive to the ALK 
inhibitor crizotinib. Cell viability was assessed by measuring ATP content after 5 days of 
treatment. Data are expressed as average ± s.d. of three independent experiments. (h) 
Crizotinib treatment downregulates MAPK and PI3K pathways in C10 cells harboring the 
ALK genetic rearrangement. C10 cell lines were treated with ALK inhibitor 1µM crizotinib 
for 12h, after which whole-cell extracts were subjected to western blot analysis. 
 
Figure 5. Overexpressed kinase genes are therapeutic targets in CRC. (a)  RNA seq 
analysis of the indicated cell lines shows overexpression of TK outlier originally identified 
by microarray data analysis. FPKM: Fragments Per Kilobase of exon per Million fragments 
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mapped. (b) Drug profiling with kinase inhibitors. The indicated cell lines were treated with 
crizotinib (ALK inhibitor) 240nM, CEP701 (TRK inhibitor) 100nM, AZD4547 (FGFR 
inhibitor) 100nM, ponatinib45 (RET inhibitor) 100Nm or nilotinib (KIT and PDGFRA 
inhibitor) 240nM for 5 days. Viability was then assessed by measuring ATP content.   
   
Fig. 6. NTRK1 and ALK molecular alterations in CRC specimen. (a) Scatter plot 
representation of transcriptional outlier kinases in 352 CRC tissue samples from the TCGA 
database. Red circles highlight samples with Z-scores values>6. (b-c) 
Immunohistochemistry based identification of FFPE CRC displaying Trk-A protein 
overexpression. 1/742 samples was markedly positive for Trk-A overexpression. In panel b 
original 4x magnification , scale bar=500µm; in panel c  original 20x magnification, scale 
bar=100µm.(d) Break-apart FISH analysis revealed NTRK1 gene rearrangement in the 
FFPE sample positive by IHC (original 63x magnification, scale bar=10µm). (e-f) 
Immunohistochemistry based identification of FFPE CRC displaying ALK protein 
overexpression. 1/742 samples was markedly positive for ALK overexpression. In panel e 
original 4x magnification, scale bar=500µm; in panel f original 20x magnification, scale 
bar=100µm)   (g) Break-apart FISH analysis revealed ALK gene rearrangement in the 
FFPE sample positive by IHC (original 63x magnification, scale bar=10µm). 
 






   
  
Supplementary Figure 1: Tissue of Origin analysis on 152 cell lines. (a) Heatmap representation of the 30 “Tissue scores” for the 152 cell lines. 
The scores summarize the global expression of the tissue specific genes for each one of the 30 tissues analyzed. (b) Plot representation of the 
weighed expression of the colon genes versus skin genes. Circle highlights COLO741 cells showing high “skin” score. (c) Log2 expression of the 
skin-specific tyrosinase (TYR) gene in 152 cell lines. Circle highlights COLO741 cells showing an outlier expression profile for the TYR gene. (d) Plot 
representation of the weighed expression of the colon genes versus small intestine genes. Circle highlights Hutu80 cells displaying high “small 
intestine” score. 
 
  
Supplementary Figure 2. Cetuximab response curves in 150 CRC cell lines. 150 cell lines of colorectal origin were treated with increasing 
concentrations of cetuximab for 4 days and cell viability was assessed by measuring ATP content. Data are expressed as percent viability compared 
with medium-only treated cells. Based on their response cells can be classified in sensitive (red lines); partially sensitive (green lines) and resistant 
(blue lines) to cetuximab treatment. 
 
  Supplementary Figure 3. Cetuximab effect on CRC cell lines. (a) Cell viability of each CRC cell line at clinical relevant concentration of 10µg/ml of 
cetuximab after 4 days of treatment (indicated by yellow dots) closely parallel AUC values. (b-e) Analysis of cell viability after 4-5 days of cetuximab 
treatment indicates net loss of cells compared to the number of cells at time “0”, in  three representative ‘sensitive’ cell models, even at clinical 
relevant dose of 10 µg/ml of cetuximab (b-d); while cetuximab exerts mainly a cytostatic effect (reduction of growth rate) on the intermediate cell lines 
LIM1215 (e). Data are expressed as percent viability compared to the number of cells at day “0”. 
 
 
 
 
 
 
  
Supplementary Figure 4: Expression based classification of CRC cell lines. (a) CRCassigner (CRCA) is the reference classifier. Enrichment 
matrix (Bonferroni-corrected hypergeometric p-values) comparing members of CRCA subtype versus others expression-based CRC classifiers. 
Orange highlighting indicates enrichment p-values< 0.05, green highlighting indicates depletion p-values< 0.05. (b) Graphic representation of the 
consensus across the intrinsic subtypes identified in cell lines by CRCassigner (CRCA) by Sadanandam et al. and other four different classification 
systems. The number of cell lines significantly assigned to each subtype (FDR<0.2) is reported.  
 
  
Supplementary Figure 5. Characterization of oncogenic TPM3-NTRK1 gene fusion in KM12 cells. (a) RNA seq analysis identified gene fusion 
event between exon 7 of the TPM3 gene and the exon10 of NTRK1 gene in the KM12 CRC cell line. (b) PCR on the cDNA of KM12 cell lines 
confirmed the TPM3-NTRK1 gene rearrangements. KM12SM cells, a derivate of the KM12 cells, were used as positive control. (c) Break apart FISH 
analysis of TPM3-NTRK1 in KM12 cells shows clear separation of green (5’) and red (3’) signals corresponding to the NTRK1 gene. Scale bars, 10µm.  
(d) Western blot analysis confirmed overexpression of the TRKA protein (codified by NTRK1 gene) in KM12 cells, at a molecular weight compatible 
with TPM3-NTRK1 translocation. (e) RNAi knockdown of NTRK1 inhibits cell proliferation of KM12 cells harboring theTPM3-NTRK1 fusion gene. KM12 
cells were analyzed by ATP lite proliferation assay 5 days after transfection with NTRK1-specific pooled siRNAs, scrambled siRNA, or transfection 
reagent (mock). Data are expressed as average ± s.d. of three independent experiments. si-RNA mediated downregulation of NTRK1 levels were 
verified by western blot. (f) KM12 cells, resistant to the EGFR inhibitor cetuximab, are sensitive to the TRK inhibitor CEP701. Cell viability was 
assessed by measuring ATP content after 5 days of treatment. Data are expressed as average ± s.d. of three independent experiments. (g) CEP701 
treatment downregulates MAPK and PI3K pathways in KM12 cells harboring NTRK1 genetic rearrangment. KM12 cells were treated with 1µM CEP701  
for 12h, after which whole-cell extracts were subjected to western blot analysis.  
  
 
 
 
 
 
 
Supplementary Figure 6. Oncogenic addiction to FGFR2 genetic amplification. (a) gDNA RTPCR identified FGFR2 gene copy number increase in 
the NCIH716 CRC cell line. (b) Western blot analysis confirmed overexpression of FGFR2 protein in the NCIH716 cells. (c) RNAi knockdown of FGFR2 
inhibits NCIH716 cell proliferation overexpressing the tyrosine kinase receptor. Cells were analyzed by ATP lite proliferation assay 5 days after 
transfection with FGFR2-specific pooled siRNAs, scrambled siRNA, or transfection reagent (mock). Data are expressed as average ± s.d. of three 
independent experiments. si-RNA mediated downregulation of FGFR2 levels were verified by western blot analysis. (d) NCIH716 cell lines, resistant to 
EGFR inhibitor cetuximab, are sensitive to FGFR inhibitor AZD4547. Cell viability was assessed by measuring ATP content after 5 days of treatment. 
Data are expressed as average ± s.d. of three independent experiments. (e) AZD4547 treatment downregulates MAPK and PI3K pathways in NCIH716 
cells harboring FGFR2 gene copy number increase. NCIH716 cells were treated with 0.5µM AZD4547 for 12h, after which whole-cell extracts were 
subjected to western blot analysis. 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 7. Oncogenic addiction to overexpressed NTRK2 and RET kinases. (a) RNAi knockdown of NTRK2 inhibits cell 
proliferation of SNU503 cell line. SNU503 cells were analyzed by ATP lite 5 days after transfection with NTRK2-specific pooled siRNAs, or transfection 
reagent (mock). Data are expressed as average ± s.d. of three independent experiments. si-RNA mediated downregulation of NTRK2 levels were 
verified by cDNA RTPCR. (b) SNU503 cells, resistant to the EGFR inhibitor cetuximab, are sensitive to the TRK inhibitor CEP701. Cell viability was 
assessed by measuring ATP content after 5 days of treatment. Data are expressed as average ± s.d. of three independent experiments. (c) Treatment 
with TRK inhibitor CEP701 initiates apoptosis in NTRK2-dependent SNU503 CRC cells. Protein lysates were analyzed by western blot after 3 days of 
treatment with 1µM CEP701. (d) Western blot analysis confirmed overexpression of RET protein in NCIH716 cells. (e) NCIH716 cells, resistant to the 
EGFR inhibitor cetuximab, are sensitive to the RET inhibitor ponatinib and to the FGFR inhibitor AZD4547. Cell viability was assessed by measuring 
ATP content after 5 days of treatment. Data are expressed as average ± s.d. of three independent experiments. (f) RNAi knockdown of RET inhibits cell 
proliferation in the NCIH716 cells. NCIH716 cells were analyzed by ATP lite proliferation assay 5 days after transfection with RET-specific pooled 
siRNAs, scrambled siRNA, or transfection reagent (mock). Data are expressed as average ± s.d. of three independent experiments. si-RNA mediated 
downregulation of RET levels were verified by western blot analysis.    
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 8. Functional validation of KIT and PDGFRA overexpression. (a) Western blot analysis confirmed overexpression of KIT 
protein in HCA24 cell lines. (b) RNAi knockdown of KIT inhibits cell proliferation in HCA24 cells. HCA24 cells were analyzed by ATP lite 5 days after 
transfection with KIT-specific pooled siRNAs, scrambled siRNA, or transfection reagent (mock). Data are expressed as average ± s.d. of three 
independent experiments. si-RNA mediated downregulation of KIT levels were verified by western blot. (c) RNAi knockdown of KIT initiates apoptosis 
in KIT-dependent HCA24 CRC cell lines. Protein lysates were analyzed by western blot 3 days after transfection with KIT-specific pooled siRNAs, 
scrambled siRNA, or transfection reagent (mock). (d) HCA24 cells, resistant to the EGFR inhibitor cetuximab, are resistant also to the KIT kinase 
inhibitors nilotinib or imatinib. Cell viability was assessed by measuring ATP content after 5 days of treatment. Data are expressed as average ± s.d. of 
three independent experiments. (e) Western blot analysis confirmed overexpression of PDGFRA protein in CACO2 cell lines. (f-g) CACO2 cells are not 
addicted to the PDGFRA overexpression. RNAi knockdown of PDGFRA failed to induce apoptosis. Protein lysates were analyzed by western blot 3 
days after transfection with PDGFRA-specific pooled siRNAs, scrambled siRNA, or transfection reagent (mock). (h) CACO2 cell lines, resistant to the 
EGFR inhibitor cetuximab, are resistant also to the PDGFRA kinase inhibitors nilotinib or imatinib. Cell viability was assessed by measuring ATP 
content after 5 days of treatment. Data are expressed as average ± s.d. of three independent experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 9. Full lengths western blot of Figure 4. (4e) C10 CRC cells overexpress  ALK protein. (4f) RNAi knockdown of ALK 
inhibits cell proliferation of C10 cell line harboring the EML4-ALK fusion gene. (4h) Crizotinib treatment downregulates MAPK and PI3K pathways 
in C10 cells.  
 
 
 
 
 
  Supplementary Figure 10. Full lengths western blot of Supplementary Figure 5. (S5d) KM12 CRC cells overexpress  TRKA protein. (S5e) RNAi knockdown of TRKA inhibits cell proliferation of KM12 cell line harboring the TPM3-NTRK1 fusion gene. (S5g) CEP701 treatment 
downregulates MAPK and PI3K pathways in KM12 cells.  
 
 
Supplementary Figure 11. Full lengths western blot of Supplementary Figure 6. (S6b) NCIH716 CRC cells overexpress  FGFR2 protein. 
(S6c) RNAi knockdown of FGFR2 inhibits cell proliferation of NCIH716 cell line harboring the FGFR2 gene amplification. (S6e) AZD4547 treatment 
downregulates MAPK and PI3K pathways in NCIH716 cells.  
 
 
 
 
 
 
 
Supplementary Figure 12. Full lengths western blot of Supplementary Figure 7. (S7c) Treatment with TRK inhibitor CEP701 initiates apoptosis 
in NTRK2-dependent SNU503 CRC cells. (S7d) NCIH716 CRC cells overexpress RET protein. (S7f) RNAi knockdown of RET inhibits cell 
proliferation of NCIH716 cell line harboring the RET overexpression 
 
 
 
 
Supplementary Figure 13. Full lengths western blot of Supplementary Figure 8. (S8a) HCA24 CRC cells overexpress  KIT protein. (S8b) 
RNAi knockdown of KIT inhibits cell proliferation of HCA24 cells. (S8c) RNAi knockdown of KIT initiates apoptosis in KIT-dependent HCA24 CRC 
cells. (S8e) CACO2 CRC cells overexpress  PDGFRA protein. (S8bf) RNAi knockdown of PDGFRA does not affect cell proliferation of CACO2 
cells. (S8g) RNAi knockdown of PDGFRA does not induce apoptosis in CACO2 CRC cells. 
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C10 ECACC 12022901 January  2013 X Y 11 12 10 13 13 11 30 31.2 6 9.3 8 9 14 15 MSI WT WT WT WT WT positiv e 562.44 0 -3.57 -0.96 -3.84 -1.41 -0.97 1.05 6.62 -0.71
C106 ECACC 12022906 January  2013 X 10 11 12 8 10 8 14 12 13 32.2 6 10 11 18 MSS WT WT p.G12C WT WT positiv e 4972.23 0 1.94 6.94 3.41 12.46 19.31 20.78 24.39 30.06
C125PM ECACC 12022909 January  2013 X 11 14 9 8 10 11 12 9 28 8 8 17 19 MSS WT WT p.K117N WT WT positiv e 1048.79 0 -4.71 8.32 9.09 9.18 17.15 0.28 4.83 6.65
C146 Lindy  Durranta UK February  2012 X 12 13 10 12 8 11 12 13 29 32 2 7 9 3 8 11 14 18 19 MSI WT WT p.G13D WT p.E545K positiv e 634.22 0 0.14 4.84 0.45 -1.41 1.75 2.13 3.85 3.32
C170 Lindy  Durranta UK February  2012 X Y 12 13 10 12 8 11 12 13 29 32 2 7 9 3 8 11 18 19 MSI WT WT p.G13D WT p.E545K positiv e 986 56 0 -1 00 2 15 2 84 3 40 -1 09 3 35 5 29 6 90
C32 ECACC 12022908 January  2013 X 10 11 11 9 8 11 9 28 30 8 9 9 14 18 MSS WT p.G12D WT WT WT positiv e 524 23 0 2 48 -6 76 -6 76 -3 28 -2 73 -4 12 7 41 1 50
C70 ECACC 12022903 January  2013 X 12 10 9 12 11 12 29 31 2 6 9 3 8 11 17 18 MSS WT WT WT WT WT positiv e 12933 35 0 6 02 5 05 19 10 44 51 52 09 60 04 67 78 66 81
C75 ECACC 12022907 January  2013 X Y 12 8 12 9 11 10 13 8 11 31 8 9.3 10 17 MSS WT WT WT WT WT positiv e 15355.71 0 11.98 42.74 55.58 66.86 78.34 77.90 77.63 74.94
C80 ECACC 12022904 January  2013 X Y 10 12 11 12 10 11 8 11 9 10 28 29 6 7 8 12 14 18 MSS WT WT p.A146V WT WT positiv e 2986.99 0 -0.86 0.45 1.36 2.01 6.20 4.44 15.03 24.44
C84 ECACC 12022902 January  2013 X 11 12 12 11 11 12 13 33.2 7 9.3 8 9 14 15 MSS WT WT p.G12A WT WT positiv e 7041.12 0 8.79 10.71 21.44 23.47 27.20 37.18 36.78 33.64
C99 ECACC 12022905 January  2013 X 10 11 11 12 9 11 8 14 11 13 28 30 8 9.3 8 10 16 17 MSS WT WT WT WT WT positiv e 15079.23 0 11.68 34.14 48.70 59.43 68.08 72.40 76.18 78.64
CACO2 ATCC HTB-37 Bef ore 2010 X 9 11 12 13 11 12 11 13 14 12 13 30 32 6 9 11 16 18 MSS WT WT WT WT WT positiv e 2887.05 0 4.35 12.51 19.99 13.94 15.20 11.60 15.94 14.05
CAR1 JCRB JCRB0207 April 2010 X 11 10 8 12 9 12 9 32 2 6 8 14 18 MSS WT WT WT WT WT positiv e 4954 64 0 -8 70 -2 74 5 06 10 52 15 53 22 83 24 39 29 19
CCK81 JCRB JCRB0208 March 2012 X 10 13 11 12 13 8 8 1 10 3 12 9 12 13 9 10 28 31 6 8 9 11 14 18 MSI WT WT WT WT WT positiv e 15413 17 0 28 03 44 06 63 09 67 99 73 21 73 29 77 69 80 15
CL11 DSMZ ACC467 October 2010 X Y 11 12 9 10 13 14 11 13 31 32 2 6 9 8 16 17 MSS WT WT p.Q61H WT WT positiv e 1095 11 0 2 30 2 94 2 23 2 18 4 67 5 59 6 00 4 89
CL14 DSMZ ACC504 October 2010 X 12 11 11 12 8 12 11 13 28 29 6 8 8 16 18 MSS WT WT WT WT WT positiv e 10695.69 0 15.39 29.32 35.77 40.43 47.75 48.51 55.50 55.72
CL34 DSMZ ACC520 October 2010 X 11 16 9 11 10 15 11 13 9 11 30 6 7 8 10 15 18 MSI WT WT WT p.V600E WT positiv e 2162.36 0 0.56 0.05 -0.57 7.86 7.56 7.20 12.61 11.49
CL40 DSMZ ACC535 October 2010 X 10 12 11 8 9 8 11 11 12 30 32.2 6 9 8 9 16 17 MSI WT WT p.G12D WT WT positiv e 4770.78 0 0.58 6.07 7.56 4.63 16.40 17.32 24.01 30.39
CO115 Dr  Hamelinb France July  2011 X 11 12 13 14 10 12 7 10.3 12 16 10 11 34.2 35 9 9.3 8 10 15 20 MSI WT WT WT p.V600E WT null 2196.48 0 2.75 1.98 4.47 5.34 7.11 8.63 11.02 13.60
COCM1 JCRB JCRB0257 April 2010 X 12 11 12 9 11 10 12 13 29 31 7 9 8 16 17 MSS WT WT WT WT WT positiv e 15779.12 0 18.12 28.69 49.17 58.39 70.60 74.39 78.79 84.87
COGA1 Prof  Huberc Austria Nov ember 2011 X 10 11 11 12 7.3 10 8 11 9 13 27 34 9 9.3 9 11 16 18 MSI WT WT WT WT WT positiv e 13301.17 0 -1.30 4.31 37.70 53.44 59.94 67.64 66.21 68.21
COGA12 Prof  Huberc Austria Nov ember 2011 X 9 11 11 15 12 13 14 15 11 12 30 30 2 9 3 10 13 14 16 MSI WT WT WT WT WT positiv e 11155.18 0 2.47 21.53 38.73 39.15 46.98 53.12 55.49 60.62
COGA2 Prof  Huberc Austria Nov ember 2011 X 10 11 12 16 11 13 11 12 11 12 13 29 36 2 8 9 3 8 10 18 20 21 MSS WT WT p.G12S WT WT positiv e 7769 69 0 11 19 8 38 25 13 24 15 28 59 33 95 37 75 46 69
COGA3 Prof  Huberc Austria Nov ember 2011 X 10 13 12 8 11 11 1 10 12 13 10 11 30 2 31 2 7 8 8 11 17 19 MSI WT WT p.G13D WT WT null 603 64 0 -0 51 -1 71 -1 80 -1 02 -2 69 0 21 4 79 3 70
COGA5 Prof  Huberc Austria Nov ember 2011 X Y 11 13 10 11 13 11 12 29 6 11 18 MSS WT WT p.G13D WT WT positiv e 713 58 0 -1 03 -7 82 -1 07 2 29 -5 62 -1 58 9 13 0 90
COGA5L Prof  Huberc Austria Nov ember 2011 X 10 11 13 10 11 13 11 12 29 6 11 18 20 MSS WT WT p.G13D WT WT positiv e 290.48 0 -4.59 -2.84 -0.30 -2.05 -2.75 1.24 2.14 1.59
COGA8 Prof  Huberc Austria Nov ember 2011 X Y 11 12 10 12 8 11 11 12 9 11 29 31 9.3 8 17 18 MSS WT WT WT WT WT positiv e 1663.39 0 0.53 2.06 1.50 -2.73 -1.19 -0.01 5.60 20.61
COLO201 ATCC CCL-224 July  2011 X 11 12 10 13 9 10 10 12 12 13 30.2 33.2 8 9 11 15 MSS WT WT WT p.V600E WT positiv e 839.14 0 1.14 2.45 1.76 2.40 1.45 2.37 6.04 3.38
COLO205 NCI60 507320 Bef ore 2010 X 11 12 10 13 9 10 10 12 12 13 30.2 33.2 8 9 11 15 MSS WT WT WT p.V600E WT positiv e 2113.39 0 -1.14 6.75 8.14 6.59 6.03 3.82 12.52 13.49
COLO320 ECACC UK Nov ember 2011 X 11 12 9 12 11 11 12 33.2 9 8 9 15 18 MSS WT WT WT WT WT positiv e 87.20 0 1.54 -1.70 -2.04 -1.27 2.04 -1.41 0.34 1.56
COLO320DM ATCC CCL-220 July  2011 X 11 12 9 12 11 11 12 31 33.2 9 8 9 15 18 MSS WT WT WT WT WT positiv e -901.48 0 -0.98 1.96 -4.63 -9.16 -8.77 -4.25 -3.23 -5.58
COLO320HSR ECACC UK February  2012 X 11 12 9 12 11 11 12 31 33 2 8 9 8 9 15 18 MSS WT WT WT WT WT positiv e 1036 72 0 -0 99 -0 24 -1 66 -2 33 -2 90 -1 04 6 72 9 21
COLO60H CLS Germany December 2011 X Y 11 15 9 16 7 3 10 11 9 13 29 33 2 6 9 3 7 10 15 16 17 19 MSI WT WT p.A146T WT WT positiv e -110 90 0 1 48 0 41 4 03 -0 40 -2 30 -1 90 -0 68 0 95
COLO678 DSMZ ACC194 October 2010 X 12 13 14 8 12 10 13 9 27 29 9 9 3 8 16 19 MSS WT WT p.G12D WT WT positiv e -718 07 0 0 23 -1 62 0 57 -1 66 6 69 -3 44 -5 15 -3 69
COLO741 ATCC USA Bef ore 2010 X 11 13 12 9 11 12 29 32.2 7 9 8 11 17 18 --> Other analyses not done because of the melanoma origin of this cell line
COLO94H CLS Germany December 2011 X Y 11 14 12 8 11 13 27 28 7 9.3 8 15 19 MSS WT WT p.G12D WT p.E545K positiv e 915.33 0 1.56 8.21 -0.03 2.43 1.69 4.05 5.71 3.95
CX1 CLS Germany December 2011 X 11 12 11 12 10 11 11 12 29 30 6 9 8 9 17 19 MSS WT WT WT p.V600E WT positiv e 1858.22 0 -2.79 -1.88 -4.16 -1.64 1.63 4.91 7.89 16.46
DIFI Dr  Baselgad Spain Bef ore 2010 X 10 11 11 12 10 12 8 11 12 32 7 9.3 8 9 17 18 MSS WT WT WT WT WT positiv e 16133.06 0 1.39 43.45 71.45 78.26 80.82 81.32 80.82 80.33
DLD1 ATCC CCL-221 December 2012 X Y 11 12 13 10 12 8 11 12 13 29 32.2 7 9.3 8 11 18 19 MSI WT WT p.G13D WT p.E545K positiv e 98.34 0 0.54 1.49 5.87 0.36 -2.43 0.65 1.34 -0.25
FET IFOMe Italy June 2012 X 12 14 8 11 11 12 28 32.2 7 8 16 17 MSS WT WT p.G12D WT WT positiv e 1348.64 0 -0.01 3.42 0.75 2.21 2.92 4.26 8.76 6.44
GEO Prof  Tortoraf Italy February  2012 X 12 10 11 11 1 8 12 12 29 8 8 15 MSI WT WT p.G12A WT WT positiv e -490 44 0 -6 78 -5 48 -4 79 -4 01 -4 06 -3 09 -4 47 1 41
GP2D ECACC 95090714 January  2012 X 9 12 11 12 9 11 8 12 11 13 29 30 7 9 3 8 11 17 18 MSI WT WT p.G12D WT p.H1047L positiv e 5160 15 0 8 18 8 98 17 32 17 83 24 91 22 70 27 34 26 15
GP5D ECACC 95090715 January  2012 X 9 12 12 9 11 9 12 11 13 29 30 7 9 3 8 11 17 18 MSI WT WT p.G12D WT p.H1047L positiv e 7031 60 0 2 13 9 11 19 64 26 25 29 89 31 03 34 64 40 35
HCA24 ECACC 6061903 January  2012 X Y 11 13 8 11.3 12 13 11 12 28 29 6 9.3 10 11 14 18 MSS WT WT WT WT WT positiv e 5854.93 0 8.69 9.51 12.79 19.46 24.27 27.63 28.52 33.03
HCA46 ECACC 7031601 October 2009 X 11 12 11 12 10 14 10 11 11 13 30 6 9.3 8 9 17 MSS WT WT WT WT p.E542K positiv e 15201.24 0 2.57 13.63 25.43 48.26 60.06 74.20 78.20 78.51
HCA7 ECACC 6061902 Bef ore 2010 X 11 14 9 11 12 11 12 9 10 11 26 28.2 29.2 6 7 8 10 14 16 MSI WT WT WT WT WT positiv e 9731.98 0 8.00 17.10 19.77 30.46 43.52 46.98 45.85 55.85
HCC2998 NCI60 507628 May  2011 X 11 13 12 10 11 11 12 9 12 29 30 7 9.3 8 11 18 19 MSS WT WT p.A146T WT WT positiv e 825.45 0 -2.41 -2.75 -0.18 -1.20 2.07 0.48 5.55 5.14
HCT116 NCI60 507326 May  2011 X 7 10 10 11 11 12 10 12 11 13 29 30 8 9 10 8 17 22 MSI WT WT p.G13D WT p.H1047R positiv e 1638.93 0 -0.48 7.54 9.02 9.09 8.75 6.93 7.40 10.16
HCT15 NCI60 507616 May  2011 X Y 12 13 10 12 8 11 12 13 29 32 2 7 9 3 8 11 18 19 MSI WT WT p.G13D WT p.E545K positiv e -434.33 0 1.82 2.54 0.30 -0.79 0.25 0.70 -3.88 -2.20
HCT8 ATCC CCL-244 January  2012 X Y 12 13 10 12 8 11 12 13 29 32 2 7 9 3 8 11 18 19 MSI WT WT p.G13D WT p.E545K positiv e 1352 38 0 -9 65 -13 65 -19 62 -6 03 8 74 -2 35 8 38 10 64
HDC114 DKFZg Germany Nov ember 2012 X Y 11 12 10 12 11 13 28 30 6 9 3 8 14 19 MSS WT WT WT WT WT positiv e 5233 58 0 7 48 14 76 11 30 21 71 23 35 25 44 25 38 28 71
HDC135 DKFZg Germany Nov ember 2010 X 9 11 10 14 10 11 9 10 12 26 28 9 9 3 7 8 16 18 MSI WT WT WT p.V600E WT positiv e 1527 86 0 3 03 2 92 2 62 3 93 5 90 8 65 9 44 4 73
HDC142 DKFZg Germany Nov ember 2010 X 11 12 12 13 8 8 12 13 27 28 9 9.3 8 11 17 MSS WT WT WT WT WT positiv e 12203.91 0 6.68 18.01 28.37 47.06 57.97 57.17 59.84 66.77
HDC143 DKFZg Germany Nov ember 2012 X 11 12 9 10 9 10 9 12 12 13 30 32.2 7 9 8 16 MSI WT WT WT WT WT positiv e -150.05 0 -0.20 -2.88 4.18 3.67 -2.94 -3.79 -1.53 2.92
HDC54 DKFZg Germany Nov ember 2010 X Y 11 12 8 9 11 12 11 30.2 32.2 9.3 9 10 17 19 MSS WT WT WT WT WT positiv e 7716.15 0 6.14 14.31 26.04 31.80 37.72 35.53 35.71 45.55
HDC8 DKFZg Germany Nov ember 2010 X 12 12 8 10 11 13 31 9.3 8 10 15 19 MSS WT WT p.G12D WT WT positiv e 1044.27 0 -1.76 0.38 0.51 0.40 1.06 0.75 5.61 8.82
HDC82 DKFZg Germany Nov ember 2010 X 13 11 8 12 9 11 13 29 30.2 7 8 8 9 17 18 MSS WT WT WT WT WT positiv e 14156.82 0 0.31 23.99 48.85 56.07 63.37 71.55 71.34 71.69
HDC9 DKFZg Germany Nov ember 2010 X Y 10 12 13 11 12 7 13 11 12 10 12 26 31 2 6 7 9 18 19 MSI WT WT WT WT WT positiv e 1813 42 0 -0 35 5 49 6 00 6 25 8 48 6 91 12 34 5 91
HRA16 ECACC 6061905 January  2012 X Y 11 12 11 12 9 13 10 13 28 9 3 8 12 16 18 MSS WT WT WT WT WT positiv e 12342 48 0 24 46 35 51 45 52 58 48 61 22 60 77 63 53 60 11
HROC18 Dr  Linnebacherh Germany January  2012 X 12 9 11 8 11 11 12 13 30 33 2 7 8 8 17 MSS WT WT p.A146V WT p.E545K positiv e 3474 66 0 -0 05 -1 90 2 10 6 20 8 74 0 90 24 82 19 99
HROC24 Dr  Linnebacherh Germany September 2011 X Y 11 12 10 11 11 13 7 13 9 11 27 28 6 9 11 16 20 MSI WT WT WT p.V600E WT positiv e 587.69 0 3.30 1.81 3.89 1.51 2.41 7.05 2.89 0.29
HROC32 Dr  Linnebacherh Germany January  2012 X 14 12 8 11 12 11 12 31 8 9 8 11 19 MSS WT WT p.G12A WT WT positiv e 6995.80 0 3.12 8.50 17.37 20.26 21.87 24.55 40.69 37.10
HROC39 Dr  Linnebacherh Germany January  2012 X 12 13 13 12 12 13 12 29 7 9.3 8 11 16 18 MSS WT WT p.A146T WT WT positiv e 3365.57 0 -5.31 4.48 16.26 17.42 10.53 15.73 19.85 14.50
HROC46 Dr  Linnebacherh Germany January  2012 X Y 12 13 8 11 12 12 13 28 32.2 6 9.3 8 12 15 17 MSS WT WT p.G12V WT WT positiv e 1241.91 0 6.78 -4.77 4.01 13.69 4.71 12.81 9.58 -3.27
HROC69 Dr  Linnebacherh Germany January  2012 X Y 10 11 12 13 10 12 11 12 13 12 13 29 33.2 7 9.3 8 12 17 19 MSS WT WT WT WT WT positiv e 3748.48 0 6.50 10.14 16.02 16.15 14.76 17.76 17.66 22.07
HROC80 Dr  Linnebacherh Germany January  2012 X 12 12 13 9 11 8 10 30 32.2 6 8 11 17 MSS WT WT p.G12V WT WT positiv e -1710.63 0 8.40 0.96 -2.41 -7.38 -6.47 -3.96 -7.83 -13.39
HROC87 Dr  Linnebacherh Germany September 2011 X 12 9 11 9 10 14 11 13 28 29 8 11 13 16 20 MSI WT WT WT p.V600E WT positiv e 2018.73 0 -1.59 1.53 6.69 7.15 8.78 6.31 10.26 12.89
HT115 ECACC 85061104 January  2012 X 7 12 12 11 12 13 10 30 32 2 6 9 8 18 MSS WT WT WT WT WT positiv e 6596 29 0 -2 75 -0 59 7 29 13 60 21 04 25 20 30 73 45 06
HT29 NCI60 507335 May  2011 X 11 12 11 12 10 11 12 11 12 29 30 6 9 8 9 17 19 MSS WT WT WT p.V600E WT positiv e 1255 35 0 -0 55 -3 56 0 33 -0 76 -2 13 0 83 8 72 8 47
HT55 ECACC 85061105 January  2012 X 11 11 12 11 13 9 13 14 28 8 9.3 8 9 14 17 MSS WT WT WT WT WT positiv e 4242.82 0 -3.85 -0.24 2.86 12.38 17.77 16.83 23.44 22.03
HUTU80 ATCC HTB-40 Bef ore 2010 X Y 11 13 12 13 9 11 8 11 10 11 31 32.2 7 9 11 16 18 MSS WT WT WT WT WT positiv e -836.36 0 1.11 -1.51 -2.84 -2.56 -4.30 -4.68 -5.35 -2.10
KM12 NCI60 507347 May  2011 X 10 12 10 8 8.3 12 15 11 27 9.3 11 12 17 19 MSI WT WT WT WT WT null -771.80 0 -1.55 -1.36 -2.53 -4.36 -4.80 -4.90 -4.05 -2.64
KM12C KCLB 80015 Nov ember 2010 X 10 10 8 9 12 15 11 27 34.2 10 11 12 17 MSI WT WT WT WT WT null -95.10 0 -4.88 -5.91 -5.03 -5.25 -4.72 -5.11 0.42 2.48
KM12L4 KCLB 80014 Nov ember 2010 X 10 12 11 8 9 13 15 11 12 27 34 10 11 12 16 17 MSI WT WT WT WT WT null 147.82 0 -7.19 -3.96 -3.65 -3.13 -0.41 -3.48 0.16 4.92
KM12SM KCLB 80016 Nov ember 2010 X 10 12 11 8 9 13 15 11 12 27 34.2 9.3 11 12 16 17 MSI WT WT WT WT WT null -109.42 0 -6.71 -6.45 -7.05 -9.63 -7.66 -6.60 -2.08 7.77
KM20 KCLB 80017 Nov ember 2010 X 11 12 11 12 10 11 11 12 29 30 6 8 9 17 19 MSS WT WT WT p.V600E WT positiv e -2213.87 0 -10.84 -7.28 -8.22 -10.24 -9.51 -14.25 -13.25 -5.98
LIM1215 Dr  Whiteheadi Australia September 2009 X Y 10 9 12 9 10 3 8 12 8  9 11 12 29 31 9 3 10 8 15 16 MSI WT WT WT WT WT positiv e 12002 99 0 28 86 42 71 52 16 59 05 61 42 60 12 59 67 60 42
LIM1899 Dr  Walkerl Australia December 2010 X Y 10 11 14 8 9 9 12 11 29 6 9 3 9 11 17 20 MSI WT WT p.G12A WT WT positiv e 1690 11 0 -4 91 -6 70 -2 68 0 47 1 17 7 36 7 25 12 86
LIM2099 Dr  Walkerl Australia December 2010 X Y 11 11 13 8 11 29 30 9 8 19 MSS WT WT p.G12C WT WT positiv e 1168 03 0 -0 15 -0 34 1 78 3 01 13 04 4 45 4 74 6 98
LIM2405 Dr  Walkerl Australia December 2010 X Y 14 15 12 13 7 8 8 11 14 15 29 30 9.3 8 14 18 MSI WT WT WT p.V600E WT null 362.68 0 8.06 5.78 8.34 5.01 -0.03 1.18 2.70 1.25
LIM2412 Dr  Walkerl Australia December 2010 X 9 10 8 11 8 13 11 12 28 29 30 6 7 8 9 14 17 MSI WT WT WT p.V600E WT null -445.10 0 -2.97 5.11 1.32 3.12 -0.73 -3.69 -1.19 -3.22
LIM2537 Dr  Walkerl Australia December 2010 X 9 10 8 11 8 14 12 28 29 30 6 8 9 14 17 MSI WT WT WT p.V600E WT null -823.98 0 -5.89 -9.36 -13.78 -10.99 -8.65 -11.34 -6.00 4.91
LIM2550 CBA CBA-0169 September 2011 X Y 12 12 13 9 10 12 15 9 14 29 31.2 8 9 8 14 19 MSI WT WT p.Q61K WT WT positiv e 1506.88 0 9.91 18.70 19.36 10.05 14.77 11.95 5.43 5.95
LIM2551 CBA CBA-0170 September 2011 X Y 10 11 12 16 9 11 8 10 11 28 33.2 6 9.3 8 11 17 19 MSI WT WT WT p.V600E p.H1047R positiv e 113.22 0 8.58 2.51 7.83 0.45 -2.97 -0.88 -1.37 5.26
LOVO ATCC CCL-229 July  2011 X Y 11 13 14 11 12 13 9.3 10 11 8 11 9 12 29 31.2 9.3 8 9 17 18 MSI WT WT p.G13D WT WT positiv e 2196.41 0 -4.03 -2.08 -0.13 -2.45 1.56 6.62 14.27 11.55
LS1034 ATCC CRL-2158 July  2011 X Y 11 12 12 13 8 12 12 9 11 29 30 7 7 9 11 17 MSS WT WT p.A146T WT WT positiv e 568 39 0 0 75 -1 04 0 45 1 88 2 17 3 70 0 98 5 22
LS123 ATCC CCL-255 July  2011 X 10 11 11 9 9 13 13 30 31 7 8 9 16 17 MSS WT WT p.G12S WT WT positiv e -1033 79 0 -1 74 -9 35 -10 32 -4 66 -7 76 -5 77 -4 80 -4 74
LS174T ATCC CL-188 January  2011 X 10 13 14 11 15 11 10 11 13 29 31 6 7 8 9 15 17 MSI WT WT p.G12D WT p.H1047R positiv e 1675 79 0 2 26 5 40 0 37 7 94 7 77 8 93 9 72 6 18
LS180 ATCC CL-187 January  2011 X 10 13 10 15 10 11 10 11 13 29 31 6 7 8 9 15 18 MSI WT WT p.G12D WT p.H1047R positiv e -820.39 0 -6.64 -2.21 -8.36 0.20 -10.51 -5.57 -4.68 -0.90
LS411N ATCC CRL-2159 July  2011 X 10 9 16 7.3 9.3 12 13 14 11 12 29 32 34 6 8 9 16 17 MSI WT WT WT p.V600E WT null -976.45 0 -0.23 -2.18 1.09 -4.00 -2.32 -4.96 -6.12 -3.59
LS513 ATCC CRL-2134 July  2011 X Y 10 13 9 11 8 11 9 10 12 13 30 30 8 8 16 17 MSS WT WT p.G12D WT WT positiv e 1716.36 0 -1.13 1.77 2.30 4.57 6.39 7.28 8.41 10.37
MDST8 ECACC 99011801 January  2012 X 11 10 8 10 10 11 11 28 31 8 9.3 8 15 20 MSS WT WT WT p.V600K WT null 1770.32 0 -6.19 -1.71 -4.06 -6.12 -4.81 4.91 7.89 16.46
MIP101 Prof  Jessupm USA June 2012 X 12 13 10 11.3 8 11 12 13 29 32.2 7 9.3 8 11 18 19 MSI WT WT p.G13D WT p.E545K positiv e 416.29 0 -0.40 -0.90 -0.08 -0.64 -0.33 2.04 2.38 2.27
NCIH498 ATCC CCL-254 May  2012 X 12 13 8 11 9 11 9 11 29 31 7 8 15 MSS WT WT p.Q61K WT p.E545K positiv e -560.10 0 0.58 1.70 -1.96 -0.54 -2.01 0.48 -4.65 -2.56
NCIH508 ATCC CCL-253 February  2011 X 11 12 12 8 12 8 12 12 29 32 2 9 9 3 8 11 15 16 MSS WT WT WT WT p.E545K positiv e 16710 76 0 -2 45 4 06 40 08 80 64 85 36 82 92 83 42 84 31
NCIH630 KCLB 90630 Nov ember 2010 X Y 10 11 12 8 11 11 12 13 14 11 12 30 33 2 7 9 8 9 15 16 17 18 MSI WT WT WT WT WT positiv e 1094 06 0 -0 89 0 61 2 66 2 43 4 87 4 68 4 97 7 01
NCIH684 KCLB 90684 Nov ember 2010 X Y 10 11 10 11 12 11 12 31 2 9 8 9 16 17 MSS WT WT p.G12D WT WT positiv e 3521 58 0 -1 06 1 13 1 90 7 65 10 15 15 84 17 88 20 40
NCIH716 ATCC CCL-251 July  2011 X 11 11 10 11 8 11 11 12 32.2 32.2 6 9.3 8 11 16 17 MSS WT WT WT WT WT positiv e 1460.05 0 3.94 8.72 -9.14 -7.77 0.44 -7.13 9.69 15.72
NCIH747 ATCC CCL-252 Bef ore 2010 X Y 11 12 11 10 11 12 9 12 29 6 8 11 16 19 MSI WT WT p.G13D WT WT positiv e -313.64 0 -11.78 -9.76 -12.24 -9.20 -13.02 -12.32 -1.20 8.11
OUMS23 JCRB JCRB1022 40269 X 12 11 10 13 12 11 28 30 7 9.3 11 16 MSS WT WT WT p.V600E WT null 1577.07 0 6.76 2.84 3.77 1.07 -3.04 0.88 13.81 6.49
OXCO1 Prof  Cerundolon UK Nov ember 2010 X 12 12 8 12 11 11 12 30 6 9.3 9 10 16 17 MSS WT WT WT p.V600E WT positiv e 654.10 0 -7.83 -8.53 -7.11 -6.98 -6.16 -3.71 -0.44 16.06
OXCO2 Prof  Cerundolon UK Nov ember 2010 X Y 9 13 11 12 10 13 10 11 11 12 30 8 11 17 22 MSI WT WT WT WT WT positiv e 17470.11 0 24.42 41.14 68.27 79.30 83.85 88.16 86.17 89.89
OXCO3 Prof  Cerundolon UK Nov ember 2010 X 12 11 10 11 11 12 9 28 9 9 3 8 16 18 MSS WT WT p.Q61H WT WT positiv e 1076 96 0 1 22 4 51 2 97 4 54 8 96 5 30 2 01 9 76
RCM1 HSRRB JCRB0256 March 2012 X 10 12 11 11 12 10 12 11 12 29 9 8 11 20 MSS WT WT p.G12V WT WT positiv e 3360 92 0 1 45 4 40 2 19 6 01 10 58 12.99 16.51 21.62
RKO Prof  Bert Vogelsteino USA August 2010 X 8 11 11 12 13 14 8 10 11 8 11 11 12 13 28 30 6 10 9 10 11 16 MSI WT WT WT p.V600E p.H1047R positiv e 99 57 0 6.51 3 66 0 72 8 36 6 16 3 31 0 36 -2 68
RW7213 Diego Arangop Spain October 2012 X Y 11 11 10 10 12 8 10 30 31 6 11 18 MSS WT WT p.G12C WT WT positiv e 2993 63 0 3 00 7 59 7 65 11 64 13 50 14 73 15 81 14 34
SKCO1 ATCC HTB-39 July  2011 X Y 13 9 11 8 10 14 13 28 30 8 9 8 11 18 19 MSS WT WT p.G12V WT WT positiv e -898.14 0 -12.08 -10.70 -10.89 -7.41 -6.52 -7.74 -7.30 2.51
SNU1033 KCLB 719 Nov ember 2010 X 10 13 11 12 10 9 29 30 9 11 17 19 MSS WT WT p.G12D WT WT positiv e 610.88 0 -3.84 -3.08 0.08 2.06 4.51 3.03 1.21 5.55
SNU1040 KCLB 1140 Nov ember 2010 X Y 12 10 13 11 13 12 9 28 29 32 6 9 8 17 19 20 MSI WT WT WT WT WT null 6091.38 0 17.50 12.67 21.65 22.59 27.56 21.95 33.65 32.57
SNU1047 KCLB 1147 Nov ember 2010 X 9 11 8 12 8 10 10 11 9 29 32.2 9 8 11 14 21 MSI WT WT WT WT WT null -1377.24 0 -5.39 -3.12 -6.53 -7.13 -8.55 -8.17 -6.48 -6.25
SNU1181 KCLB 1181 July  2012 X 12 10 10 11 10 11 10 12 29 32 2 9 8 14 18 MSS WT WT p.G12S WT WT positiv e 2977 82 0 7 44 27.19 5.35 8.30 11.50 7.23 19.44 14.39
SNU1235 KCLB 1235 July  2012 X 12 12 8 12 13 12 30 9 8 9 17 MSS WT WT WT p.V600E WT null -2184.11 0 -0.14 -2.45 -0.45 0.50 9.24 -5.64 -11.81 -18.04
SNU1406 KCLB 1406 July  2012 X 11 12 11 12 8 11 8 9 11 12 30 33 2 6 9 3 8 11 15 18 MSS WT WT WT WT WT positiv e
SNU1411 KCLB 1411 July  2012 X 10 12 11 13 11 10 12 13 30 9 8 20 MSS WT WT p.G12C WT WT positiv e 783 28 0 -2 76 -2 04 -3 30 -4 55 -2 16 0 28 4 83 6 65
SNU1460 KCLB 1460 July  2012 X 12 11 8 11 9 12 10 30 2 31 6 7 8 11 14 18 MSS WT WT WT WT WT positiv e 12054 06 0 3 81 3 72 16 60 48 33 53 98 58 27 57 70 67 51
SNU1544 KCLB 1544 July  2012 X 11 12 12 11 12 9 11 8 14 29 30 7 9 8 14 20 21 MSI WT WT WT WT p.H1047R positiv e 2526.72 0 2.52 2.34 0.93 0.04 2.48 7.12 13.29 18.10
SNU1684 KCLB 1684 July  2012 X 9 10 10 11 9 13 8 9 10 28 9 8 10 14 17 MSI WT WT p.G13D WT WT null 7154.92 0 16.91 13.36 17.71 31.19 32.95 29.42 37.77 38.14
SNU1746 KCLB 1746 July  2012 X Y 7 9 11 12 13 14 8 11 9 9 14 28 33 6 8 9 18 MSI WT WT p.G13D WT WT positiv e -2525.53 0 11.65 17.58 1.73 0.42 -18.35 -18.02 -8.84 -13.65
SNU175 KCLB 175 Nov ember 2010 X 10 12 11 11 9 12 9 12 30 32.2 7 9 8 11 14 17 MSI WT WT WT WT WT positiv e 5176.65 0 2.05 9.80 14.31 20.70 22.47 24.77 25.53 28.18
SNU254 KCLB 254 July  2012 X 10 11 10 11 13 11 9 31 7 8 12 14 17 MSS WT WT p.G12D WT p.E545A positiv e 1417.81 0 -8.03 -2.93 -5.29 -1.91 2.18 -0.66 8.25 12.10
SNU283 KCLB 638 Nov ember 2010 X 11 13 9 11 8 11 9 12 29 30 7 9 8 11 14 19 MSS WT WT WT WT WT positiv e 10221 76 0 16 99 33 07 32 46 44 43 44 14 48 30 51.53 54.37
SNU407 KCLB 407 October 2012 X Y 10 11 10 8 10 8 10 11 12 28 29 6 7 8 14 16 MSI WT WT p.G12D WT p.H1047R positiv e 4252 95 0 -0 38 1.67 7.61 14.23 15.01 20.15 20 97 24 13
SNU479 KCLB 479 July  2012 X 11 12 13 9 12 9 11 9 11 32 2 6 7 9 12 16 17 MSS WT WT WT WT WT null 9244 47 0 26 90 14 59 45 59 39 19 49 04 37 70 53 56 40 90
SNU503 KCLB 503 October 2012 X 11 10 10 11 10 11 12 30 9 8 11 14 17 MSS WT WT WT WT WT positiv e 10216 08 0 12 32 22 79 29 75 37 89 43 18 46 83 54 14 51 75
SNU61 KCLB 61 Nov ember 2010 X 12 11 8 8 12 29 9 8 9 16 MSS WT WT p.G12D WT WT positiv e 2005.72 0 -2.60 -0.48 0.86 5.64 3.17 5.59 11.37 12.80
SNU769B KCLB 668 Nov ember 2010 X Y 11 14 14 11.3 13 9 12 12 29 31 7 8 8 18 MSI WT WT WT WT WT positiv e 11134.12 0 4.44 4.00 4.44 4.06 33.93 55.25 58.14 58.52
SNU81 KCLB 81 October 2012 X 11 13 10 11 12 9 10 9 12 30 31 7 9 8 11 16 17 MSS WT WT p.A146T WT WT positiv e 659.04 0 -0.92 2.35 -3.83 -2.86 -1.10 -1.19 6.26 3.11
SNU977 KCLB 977 July  2012 X 11 12 11 12 10 12 11 10 29 7 11 16 17 18 MSS WT WT WT WT WT positiv e 2968.09 0 -3.18 0.57 -2.33 2.09 4.32 6.72 19.90 15.63
SNUC1 KCLB 0000C1 Nov ember 2010 X 12 10 10 11 9 11 9 11 30 7 9 11 12 16 18 MSS WT WT WT WT WT positiv e 1651.74 0 2.20 5.74 7.67 5.36 5.73 3.37 8.68 11.71
SNUC2A KCLB 0000C2A Nov ember 2010 X 11 14 8 9 13 16 9 12 8 9 9 8 15 19 MSI WT WT p.G12D WT WT positiv e -560.84 0 0.20 4.97 3.98 1.16 3.41 1.31 -2.73 -7.28
SNUC2B KCLB 0000C2B Nov ember 2010 X 11 14 8 9 13 16 9 10 8 9 9 8 15 18 MSI WT WT p.G12D WT WT positiv e 3201 17 0 -0 41 1 39 5 80 4 65 11 92 13 14 16 61 18 35
SNUC4 KCLB 0000C4 Nov ember 2010 X Y 10 8 9 7 3 11 12 8 9 9 10 28 30 7 8 11 14 15 MSI WT WT WT WT p.E545G null 9286 57 0 -9 74 7 31 18 89 33.14 35 35 44 69 48 32 47 80
SNUC5 KCLB 0000C5 Nov ember 2010 X 11 13 11 12 12 8 8 13 29 31 2 6 9 8 15 MSI WT WT WT p.V600E p.H1047R positiv e 542 73 0 -0 40 -1 84 -5 16 -0 83 -0 73 -3 68 4 94 4 72
SW1116 ATCC CCL-233 May  2011 X Y 10 11 11 12 12 11 14 9 12 28 29 6 8 11 14 19 MSS WT WT p.G12A WT WT positiv e 228.80 0 -5.54 -5.10 -7.71 -3.47 -2.57 -1.16 2.00 2.42
SW1222 Dr Herly nq USA July  2011 X Y 11 9 10 12 9 9 10 29 7 10 18 MSS WT WT p.A146V WT WT null 1308.71 0 0.10 3.23 1.35 5.25 5.34 6.47 7.09 6.11
SW1417 ATCC CCL-238 May  2011 X 12 12 12 9 11 12 11 12 29 32.2 33.2 6 8 8 11 15 18 MSS WT WT WT p.V600E WT positiv e 1133.22 0 -0.65 0.19 -0.61 -0.58 -1.27 -1.94 8.32 8.71
SW1463 ATCC CCL-234 May  2011 X 11 12 13 14 9 12 13 11 30 31.2 6 7 8 11 16 MSS WT WT p.G12C WT WT positiv e 2042.16 0 4.81 0.27 4.27 1.68 11.23 -0.38 13.19 13.18
SW403 ATCC CCL-230 40634 X 10 13 11 8 9 13 10 12 28 29 6 8 9 14 18 MSS WT WT p.G12V WT p.Q546K positiv e 4077.36 0 -3.28 -1.41 4.33 7.69 11.45 17.40 18.75 27.30
SW48 ATCC CCL-231 March 2011 X 9 10 10 14 9 10 11 12 11 13 28 31 8 6 9 3 18 20 MSI WT WT WT WT WT positiv e 1219 28 0 -5 68 -6 77 6 37 0 50 6 23 7 12 5 32 6 66
SW480 ATCC CCL-228 January  2011 X 13 14 13 8 12 13 30 30 2 8 11 16 MSS WT WT p.G12V WT WT positiv e 1025 71 0 -4 82 1 63 2 54 3 80 1 70 5 60 3 42 8 18
SW620 ATCC 507424 May  2011 X 13 14 13 8 9 12 9 13 30 30 2 8 11 16 MSS WT WT p.G12V WT WT positiv e -362 57 0 0 84 -3 28 -6 86 -8 96 -9 77 -9 12 -0 25 2 88
SW837 ATCC CCL-235 May  2011 X 10 12 9 12 13 12 28 31 2 9 3 8 9 15 19 MSS WT WT p.G12C WT WT positiv e 1859 80 0 0 03 2 69 5 42 8 45 10 55 11 82 7 90 9 43
SW948 ATCC CCL-237 40634 X 12 11 9 11 10 11 11 12 25.2 29 6 9.3 8 11 16 18 MSS WT WT p.Q61L WT p.E542K positiv e 51.08 0 -0.91 0.65 0.87 1.08 0.06 -0.92 0.07 1.38
T84 ATCC CCL-248 July  2011 X 10 12 8 10 9 9 10 11 31 6 9 8 11 17 18 MSS WT WT p.G13D WT p.E542K positiv e 2326.70 0 -1.11 -0.07 2.24 5.29 5.14 6.96 15.59 10.60
V411 Prof  Markov itzr USA March 2012 X 11 12 13 9 11 9 12 11 12 29 32.2 9 8 15 MSS WT WT p.G13D WT WT positiv e 807.71 0 1.16 0.18 2.50 -1.90 2.74 2.84 4.46 4.68
V457 Prof  Markov itzr USA March 2012 X 11 14 11 16 12 13 11 12 11 12 29 32 7 9 8 9 18 MSI WT WT p.G12D WT WT null -399.99 0 5.71 3.31 4.41 2.24 -0.29 -4.57 -0.38 -3.12
V481 Prof  Markov itzr USA March 2012 X 7 12 8 11 8 11 13 11 15 31 7 8 9 17 18 21 MSI WT WT p.G12C WT p.Q546P null -2706.95 0 -3.90 -4.88 -7.07 -8.04 -10.72 -10.22 -13.27 -17.06
V703 Prof  Markov itzr USA March 2012 X 9 12 13 11 9 12 9 29 2 31 9 9 3 7 10 18 21 MSI WT WT p.G12D WT WT positiv e 2291 68 0 0 35 4 37 6 91 6 51 7 85 9 04 11 93 13 41
VACO432 Prof  Bert Vogelsteino USA August 2010 X 9 10 9 10 15 16 11 13 11 12 11 14 28 33 2 8 9 3 7 8 14 19 MSI WT WT WT p.V600E WT positiv e 1876 61 0 0 56 4 25 10 97 8 55 15 00 14 11 9 25 5 09
VACO5 Prof  Markov itzr USA February  2012 X 11 13 1 13 10 9 13 9 13 24 2 29 9 3 9 11 14 18 MSI WT WT WT p.V600E p.H1047R positiv e 1544 19 0 7 12 3 34 1 73 4 74 6 94 6 55 7 99 8 42
VACO6 Prof  Markov itzr USA February  2012 X Y 11 11 7 10 11 14 10 12 13 29 31 2 9 9 3 8 10 18 20 22 MSI WT WT WT p.V600E WT positiv e 3625 00 0 22 28 -1 05 11 78 16 16 20 34 14 28 18 95 19 21
WIDR Prof  Bernardss The Netherland September 2011 X 11 12 11 12 10 10 11 12 11 12 29 30 6 9 8 9 17 19 MSS WT WT WT p.V600E WT positiv e -547.13 0 -6.43 -8.00 -6.56 -6.12 -5.45 -6.32 -4.01 2.36
Section 3. Microsatellite Instability (MSI/MSS) and mutational status Section 4. Pharmacological profile of response to cetuximab treatment 
List of the genetic status of the 151 CRC cell l ines for the HRAS, NRAS, KRAS, BRAF and PIK3CA 
reported hotspots. MSI/MSS status are reported.  PTEN protein expression, evalueted by western blot 
analysis, is also indicated. Positive: PTEN protein detected. Null: PTEN protein absent.             
CRC cells were treated with indicated concentrations of cetuximab for 4 days, after that cell viabil ity was assessed by ATP content. For 
each cell l ine the area under the concentration–inhibition curve (Index AUC) (see Methods) is reported. For each drug concentration the 
percentage (%) of growth inhibition at indicated concentrations is l isted. Cetux: cetuximab
Supplmentary Data 1. Molecular and pharmacological annotation of 151 CRC cell lines.This table is subdivided in four sections, reporting: (i)  identification name 
and acquisition sources, (i i) STR ​​profi les, (i i i) MSI and mutational annotations and (iv) pharmacological annotations. On top of the sections, a note provides details and 
a brief description of the section content. Footnotes list contact details of scientists who provided the indicated cell l ines. 
Section 2. Short Tandem Repeats (STR) profilesSection 1. Cell lines names, sources and acquisition details
CRC cell l ines identity was checked by Short Tandem Repeats (STR) profiles through simultaneously amplification of ten STR loci (D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO and amelogenin). Resulting cell l ine STR 
profiles were cross-compared and matched with the available ATCC STR, DSMZ, JCRB, Korean Cell Line Bank, ECCAC, and CellBank Australia repositories online databases. Cell l ines derived from the same individual (similar STR) are highlighted by 
the same color.
Locus AMEL Locus CSF1PO Locus D5S818 Locus D7S820 Locus D13S317 Locus D16S539 Locus D21S11 Locus TH01 Locus TPOX Locus v WA
GEO ID Cell Line Sadanandam class BH.FDR Marisa class BH.FDR
Budinska 
Class BH.FDR
De Sousa E 
Melo class BH.FDR
Roepman 
Class BH.FDR
GSM1448103 COGA12 Enterocyte 0.000990 C6 0.001235 Subtype B 0.001794 CCS1 0.030964 B-Type 0.020127
GSM1448130 HDC54 Enterocyte 0.000990 C6 0.000751 Subtype B 0.001776 CCS1 0.002580 B-Type 0.003871
GSM1448175 DIFI Enterocyte 0.000990 C6 0.000751 Subtype A 0.001794 CCS1 0.002580 B-Type 0.003871
GSM1448185 HDC143 Enterocyte 0.000990 C6 0.000751 Subtype B 0.185241 CCS3 0.401371 B-Type 0.252024
GSM1448199 C32 Enterocyte 0.000990 C6 0.000751 Subtype E 0.005636 CCS1 0.002580 B-Type 0.003871
GSM1448208 SNU479 Enterocyte 0.000990 C6 0.000751 Subtype A 0.001776 CCS1 0.002580 B-Type 0.006136
GSM1448215 NCIH684 Enterocyte 0.001973 C5 0.003195 Subtype C 0.001776 CCS1 0.142241 B-Type 0.006136
GSM1448110 V481 Enterocyte 0.002293 C3 0.000751 Subtype A 0.001510 CCS2 0.392312 A-Type 0.169639
GSM1448221 V411 Enterocyte 0.004915 C6 0.002475 Subtype B 0.201545 CCS1 0.006773 B-Type 0.779002
GSM1448205 SNU1684 Enterocyte 0.007631 C6 0.024364 Subtype D 0.234064 CCS2 0.268919 C-Type 0.061305
GSM1448157 SNU1411 Enterocyte 0.013285 C3 0.010619 Subtype E 0.762087 CCS3 0.910059 C-Type 0.992003
GSM1448154 FET Enterocyte 0.016416 C6 0.206853 Subtype C 0.146926 CCS1 0.637107 A-Type 0.036089
GSM1448189 SNU1040 Enterocyte 0.024998 C6 0.002706 Subtype D 0.004473 CCS3 0.279400 C-Type 0.127088
GSM1448220 VACO6 Enterocyte 0.025762 C3 0.016990 Subtype C 0.001510 CCS2 0.008386 A-Type 0.003871
GSM1448151 COGA5L Enterocyte 0.042272 C5 0.032518 Subtype B 0.210863 CCS1 0.428267 B-Type 0.838494
GSM1448080 HROC69 Enterocyte 0.048097 C6 0.017273 Subtype B 0.217986 CCS1 0.191832 B-Type 0.159829
GSM1448127 SNUC4 Enterocyte 0.059593 C2 0.001235 Subtype B 0.001794 CCS1 0.004328 A-Type 0.232881
GSM1448099 COGA1 Enterocyte 0.079418 C2 0.012915 Subtype E 0.036904 CCS2 0.021943 A-Type 0.004645
GSM1448111 HT115 Enterocyte 0.149772 C2 0.340635 Subtype C 0.001776 CCS2 0.088469 A-Type 0.059678
GSM1448203 C84 Enterocyte 0.712161 C1 0.006564 Subtype E 0.325500 CCS1 0.213236 B-Type 0.207267
GSM1448202 C80 Goblet 0.000936 C3 0.014100 Subtype B 0.002157 CCS1 0.040515 B-Type 0.110592
GSM1448070 HDC9 Goblet 0.000990 C3 0.000751 Subtype A 0.002922 CCS2 0.057591 C-Type 0.174684
GSM1448071 HROC24 Goblet 0.000990 C3 0.000751 Subtype C 0.001510 CCS2 0.005134 A-Type 0.003871
GSM1448087 SNUC2B Goblet 0.000990 C2 0.000751 Subtype C 0.006194 CCS2 0.048453 A-Type 0.054044
GSM1448164 LS174T Goblet 0.000990 C3 0.000751 Subtype A 0.001776 CCS2 0.859147 A-Type 0.044358
GSM1448193 SKCO1 Goblet 0.000990 C3 0.000751 Subtype A 0.458161 CCS1 0.123550 C-Type 0.839294
GSM1448206 SNU1746 Goblet 0.000990 C3 0.000751 Subtype C 0.001776 CCS2 0.005920 A-Type 0.784579
GSM1448216 SNU175 Goblet 0.000990 C3 0.000751 Subtype C 0.001794 CCS2 0.229650 A-Type 0.053998
GSM1448141 LS513 Goblet 0.001267 C3 0.000751 Subtype A 0.090861 CCS1 0.300701 B-Type 0.873060
GSM1448119 CL34 Goblet 0.006785 C2 0.000751 Subtype C 0.008933 CCS2 0.009710 A-Type 0.293298
GSM1448139 LS180 Goblet 0.009365 C2 0.002249 Subtype A 0.185241 CCS2 0.501343 C-Type 0.796206
GSM1448188 KM12SM Goblet 0.009535 C2 0.011895 Subtype A 0.231325 CCS2 0.011940 A-Type 0.272147
GSM1448120 CX1 Goblet 0.010379 C3 0.116078 Subtype C 0.072921 CCS2 0.450579 A-Type 0.484628
GSM1448073 KM12 Goblet 0.010895 C3 0.006564 Subtype A 0.242989 CCS2 0.078334 A-Type 0.212048
GSM1448186 KM12C Goblet 0.012324 C3 0.005730 Subtype A 0.086067 CCS2 0.303117 C-Type 0.337246
GSM1448094 COLO60H Goblet 0.013752 C2 0.001006 Subtype B 0.016922 CCS1 0.302302 A-Type 0.010960
GSM1448159 SNU81 Goblet 0.019742 C3 0.025757 Subtype C 0.001776 CCS3 0.764465 A-Type 0.036089
GSM1448187 KM12L4 Goblet 0.090582 C2 0.005921 Subtype A 0.637688 CCS2 0.600230 A-Type 0.747456
GSM1448204 C99 Goblet 0.146863 C3 0.185111 Subtype A 0.150970 CCS1 0.152360 B-Type 0.708839
GSM1448217 SNU407 Goblet 0.161949 C2 0.000751 Subtype C 0.028037 CCS2 0.162952 A-Type 0.635107
GSM1448136 LIM1899 Goblet 0.162815 C1 0.517844 Subtype A 0.273869 CCS2 0.446369 B-Type 0.826927
GSM1448218 SNU769B Goblet 0.292993 C3 0.029487 Subtype C 0.001794 CCS1 0.105451 A-Type 0.006136
GSM1448081 V457 Goblet 0.332352 C2 0.001006 Subtype A 0.487231 CCS2 0.026638 A-Type 0.033065
GSM1448181 C125PM Goblet 0.349946 C5 0.001006 Subtype B 0.002922 CCS1 0.673820 B-Type 0.339217
GSM1448172 COLO205 Goblet 0.350034 C3 0.386958 Subtype E 0.491730 CCS2 0.876460 C-Type 0.497533
GSM1448179 HT29 Goblet 0.474598 C1 0.516591 Subtype C 0.001510 CCS3 0.073678 A-Type 0.424097
GSM1448198 C146 Goblet 0.683481 C2 0.114711 Subtype E 0.827113 CCS3 0.900633 C-Type 0.438027
GSM1448169 HCC2998 Goblet 0.709348 C2 0.720713 Subtype B 0.771782 CCS1 0.970676 A-Type 0.881046
GSM1448124 VACO432 Goblet 0.817685 C2 0.000751 Subtype C 0.051803 CCS2 0.005134 A-Type 0.072679
GSM1448135 LIM2537 Inflammatory 0.000936 C2 0.000729 Subtype C 0.001776 CCS2 0.004328 A-Type 0.014506
GSM1448149 CL40 Inflammatory 0.000936 C6 0.000751 Subtype A 0.455554 CCS1 0.106044 C-Type 0.966413
GSM1448069 HDC135 Inflammatory 0.000990 C2 0.000751 Subtype C 0.001776 CCS2 0.037737 A-Type 0.004645
GSM1448072 HROC87 Inflammatory 0.000990 C2 0.000751 Subtype C 0.002922 CCS2 0.009710 A-Type 0.059054
GSM1448086 SNU61 Inflammatory 0.000990 C6 0.012015 Subtype C 0.001776 CCS2 0.214830 A-Type 0.126305
GSM1448090 T84 Inflammatory 0.000990 C2 0.013625 Subtype C 0.001776 CCS1 0.002580 B-Type 0.049663
GSM1448095 HROC18 Inflammatory 0.000990 C1 0.002475 Subtype C 0.001776 CCS1 0.002580 B-Type 0.054090
GSM1448108 V703 Inflammatory 0.000990 C2 0.000751 Subtype E 0.448469 CCS1 0.213236 B-Type 0.445882
GSM1448118 LIM1215 Inflammatory 0.000990 C2 0.000751 Subtype C 0.001776 CCS2 0.002580 A-Type 0.103811
GSM1448138 LS123 Inflammatory 0.000990 C4 0.000751 Subtype C 0.001776 CCS3 0.134671 C-Type 0.015615
GSM1448147 OXCO3 Inflammatory 0.000990 C5 0.007669 Subtype C 0.001776 CCS3 0.073293 A-Type 0.058604
GSM1448158 SNU1460 Inflammatory 0.000990 C6 0.000729 Subtype C 0.002581 CCS1 0.002580 B-Type 0.059054
GSM1448195 SW837 Inflammatory 0.002593 C5 0.019594 Subtype C 0.001776 CCS3 0.572890 C-Type 0.401727
GSM1448091 WIDR Inflammatory 0.003274 C2 0.024351 Subtype E 0.807536 CCS3 0.399412 A-Type 0.437125
GSM1448150 COGA5 Inflammatory 0.003907 C5 0.003195 Subtype C 0.001776 CCS3 0.268213 C-Type 0.383461
GSM1448131 SNUC5 Inflammatory 0.006519 C2 0.000751 Subtype D 0.771897 CCS2 0.073293 C-Type 0.082238
GSM1448190 SNU1235 Inflammatory 0.007045 C4 0.073046 Subtype D 0.150440 CCS3 0.218617 C-Type 0.032815
GSM1448168 LIM2550 Inflammatory 0.009365 C2 0.005536 Subtype C 0.001776 CCS2 0.002580 A-Type 0.003659
GSM1448121 VACO5 Inflammatory 0.012810 C2 0.145403 Subtype C 0.006194 CCS2 0.002580 A-Type 0.006136
GSM1448145 NCIH747 Inflammatory 0.022430 C4 0.174720 Subtype D 0.209861 CCS3 0.789212 C-Type 0.078209
GSM1448163 LOVO Inflammatory 0.024497 C2 0.001735 Subtype E 0.051419 CCS2 0.089148 A-Type 0.818343
GSM1448076 LIM2551 Inflammatory 0.024998 C2 0.000751 Subtype C 0.001776 CCS2 0.015055 A-Type 0.003871
GSM1448074 KM20 Inflammatory 0.044482 C5 0.005162 Subtype C 0.001776 CCS2 0.031017 A-Type 0.062896
GSM1448184 HDC114 Inflammatory 0.068717 C2 0.152224 Subtype C 0.018831 CCS2 0.151899 A-Type 0.822306
GSM1448107 C170 Inflammatory 0.095037 C2 0.000751 Subtype D 0.264851 CCS2 0.073403 A-Type 0.421550
GSM1448067 CO115 Inflammatory 0.137821 C2 0.000751 Subtype C 0.008933 CCS2 0.002580 A-Type 0.003871
GSM1448075 LIM2412 Inflammatory 0.150026 C2 0.036495 Subtype E 0.636429 CCS3 0.670887 C-Type 0.204893
GSM1448174 COLO678 Inflammatory 0.319792 C4 0.054298 Subtype D 0.099640 CCS3 0.471947 B-Type 0.097957
GSM1448132 RKO Inflammatory 0.723828 C2 0.002249 Subtype E 0.713542 CCS2 0.002580 C-Type 0.361216
GSM1448165 SW48 Inflammatory 0.748892 C2 0.030819 Subtype C 0.061840 CCS2 0.114785 A-Type 0.028970
GSM1448178 HCT15 Inflammatory 0.880083 C2 0.012357 Subtype C 0.324066 CCS2 0.002580 A-Type 0.334894
GSM1448116 MIP101 Inflammatory 0.885287 C2 0.018819 Subtype B 0.304046 CCS2 0.008386 A-Type 0.013977
GSM1448140 LS411N Inflammatory 0.912018 C2 0.001235 Subtype B 0.697417 CCS2 0.002425 A-Type 0.449418
GSM1448089 SW1417 TA 0.000936 C5 0.000751 Subtype C 0.001510 CCS1 0.116897 B-Type 0.004645
GSM1448197 C106 TA 0.000936 C1 0.000751 Subtype E 0.095568 CCS1 0.002580 B-Type 0.029072
GSM1448079 HROC32 TA 0.000990 C1 0.000751 Subtype B 0.001510 CCS1 0.002580 B-Type 0.003871
GSM1448082 HT55 TA 0.000990 C1 0.000751 Subtype B 0.001510 CCS1 0.002580 B-Type 0.003871
GSM1448083 HROC39 TA 0.000990 C5 0.001006 Subtype B 0.005139 CCS1 0.002580 B-Type 0.041595
GSM1448088 SW1222 TA 0.000990 C1 0.001006 Subtype B 0.001776 CCS1 0.002580 B-Type 0.003871
GSM1448101 COGA3 TA 0.000990 C2 0.013625 Subtype B 0.156176 CCS1 0.002580 B-Type 0.003659
GSM1448109 HCA24 TA 0.000990 C3 0.009407 Subtype B 0.018051 CCS1 0.002425 A-Type 0.205840
GSM1448112 LS1034 TA 0.000990 C1 0.000751 Subtype B 0.173422 CCS1 0.002580 B-Type 0.006136
GSM1448113 SW1463 TA 0.000990 C5 0.000751 Subtype B 0.001510 CCS1 0.048406 B-Type 0.003871
GSM1448115 SNUC1 TA 0.000990 C5 0.000751 Subtype B 0.004473 CCS1 0.002580 B-Type 0.003871
GSM1448117 HRA16 TA 0.000990 C5 0.000751 Subtype B 0.006710 CCS1 0.002580 B-Type 0.003871
GSM1448128 HDC82 TA 0.000990 C5 0.000729 Subtype B 0.004473 CCS1 0.002580 B-Type 0.003871
GSM1448129 HDC142 TA 0.000990 C5 0.000751 Subtype B 0.002157 CCS1 0.002580 B-Type 0.003871
GSM1448143 NCIH630 TA 0.000990 C1 0.001471 Subtype B 0.006194 CCS1 0.003354 B-Type 0.003871
GSM1448146 OXCO2 TA 0.000990 C6 0.118519 Subtype B 0.001510 CCS1 0.002580 B-Type 0.003871
GSM1448153 COLO94H TA 0.000990 C5 0.000751 Subtype B 0.001776 CCS1 0.002425 B-Type 0.004645
GSM1448156 RW7213 TA 0.000990 C3 0.000751 Subtype A 0.001776 CCS1 0.002580 B-Type 0.205028
GSM1448167 COCM1 TA 0.000990 C6 0.000751 Subtype B 0.001776 CCS1 0.002580 B-Type 0.003871
GSM1448171 CL14 TA 0.000990 C5 0.000729 Subtype A 0.380716 CCS1 0.002580 B-Type 0.005514
GSM1448176 GEO TA 0.000990 C3 0.207590 Subtype B 0.005636 CCS1 0.027711 B-Type 0.053501
GSM1448177 HCA46 TA 0.000990 C1 0.000751 Subtype A 0.009479 CCS1 0.002580 B-Type 0.003871
Supplementary Data 2. Classification of 151 CRC cell lines into molecular subtypes according to five transcriptonal classifiers.
CRC cell lines from GSE59857 were assigned by the NTP algorithm to a molecular subtype for each of five different classifiers. For each classifier, in addition to the subtype class, the table reports the 
Benjamini-Hockberg (BH)-corrected FDR. In the BH.FDR columns, grey shading indicates low classification confidence (FDR > 0.2). 
GSM1448191 SNU1406 TA 0.000990 C5 0.000751 Subtype B 0.001776 CCS1 0.009710 B-Type 0.003871
GSM1448194 SW403 TA 0.000990 C5 0.000751 Subtype B 0.001776 CCS1 0.002580 B-Type 0.003871
GSM1448200 C70 TA 0.000990 C1 0.051278 Subtype B 0.001794 CCS1 0.002580 B-Type 0.017056
GSM1448201 C75 TA 0.000990 C1 0.231460 Subtype B 0.001794 CCS1 0.002580 B-Type 0.007575
GSM1448213 SW948 TA 0.000990 C5 0.000751 Subtype B 0.006416 CCS1 0.116036 B-Type 0.013291
GSM1448106 Gp5D TA 0.001267 C2 0.010018 Subtype B 0.002922 CCS1 0.002580 A-Type 0.159254
GSM1448114 SW1116 TA 0.001267 C5 0.000751 Subtype B 0.149920 CCS1 0.002580 B-Type 0.005514
GSM1448219 SNU1181 TA 0.001267 C5 0.000751 Subtype E 0.872426 CCS1 0.447968 A-Type 0.330043
GSM1448123 SNU283 TA 0.001610 C1 0.019548 Subtype C 0.001510 CCS1 0.002580 B-Type 0.010375
GSM1448100 COGA2 TA 0.002293 C5 0.023526 Subtype C 0.022248 CCS2 0.143282 B-Type 0.023586
GSM1448097 CCK81 TA 0.003595 C1 0.018872 Subtype B 0.001776 CCS2 0.002425 B-Type 0.677054
GSM1448214 NCIH498 TA 0.008861 C5 0.000751 Subtype B 0.748810 CCS1 0.513663 B-Type 0.003871
GSM1448098 RCM1 TA 0.075741 C1 0.000751 Subtype E 0.400633 CCS1 0.270296 B-Type 0.025545
GSM1448085 SNU1047 TA 0.096473 C2 0.000751 Subtype D 0.020879 CCS2 0.030964 C-Type 0.034726
GSM1448068 COLO201 TA 0.149543 C5 0.000751 Subtype C 0.001776 CCS2 0.053385 C-Type 0.339531
GSM1448105 GP2D TA 0.153310 C2 0.001471 Subtype B 0.013420 CCS1 0.013418 A-Type 0.158788
GSM1448142 NCIH508 TA 0.219985 C1 0.121106 Subtype A 0.005414 CCS1 0.002580 B-Type 0.791861
GSM1448212 SW620 TA 0.280308 C5 0.000751 Subtype D 0.005414 CCS3 0.460303 C-Type 0.022363
GSM1448084 HROC46 Stem 0.000936 C5 0.000751 Subtype D 0.060681 CCS1 0.160733 B-Type 0.010375
GSM1448160 CACO2 Stem 0.000936 C4 0.002002 Subtype D 0.002922 CCS1 0.270967 B-Type 0.003659
GSM1448166 SW480 Stem 0.000936 C4 0.000751 Subtype D 0.001510 CCS3 0.021943 C-Type 0.007575
GSM1448077 OUMS23 Stem 0.000990 C4 0.000751 Subtype D 0.001510 CCS3 0.008386 C-Type 0.003871
GSM1448078 SNU1033 Stem 0.000990 C4 0.008071 Subtype D 0.007686 CCS3 0.015055 C-Type 0.006709
GSM1448096 SNUC2A Stem 0.000990 C4 0.000751 Subtype D 0.005139 CCS3 0.014727 C-Type 0.020454
GSM1448122 MDST8 Stem 0.000990 C4 0.000751 Subtype D 0.001776 CCS3 0.002580 C-Type 0.003871
GSM1448134 OXCO1 Stem 0.000990 C4 0.000751 Subtype D 0.001776 CCS3 0.002580 C-Type 0.006136
GSM1448137 LIM2099 Stem 0.000990 C4 0.000751 Subtype D 0.001776 CCS3 0.002425 C-Type 0.003871
GSM1448170 CAR1 Stem 0.000990 C4 0.000751 Subtype E 0.001794 CCS3 0.029471 C-Type 0.004645
GSM1448180 HUTU80 Stem 0.000990 C4 0.000751 Subtype E 0.011042 CCS3 0.086656 C-Type 0.006136
GSM1448196 C10 Stem 0.000990 C4 0.000751 Subtype D 0.001776 CCS3 0.002425 C-Type 0.020454
GSM1448207 SNU254 Stem 0.000990 C4 0.000751 Subtype D 0.005636 CCS3 0.047736 C-Type 0.010960
GSM1448209 SNU503 Stem 0.000990 C4 0.000751 Subtype D 0.002581 CCS3 0.079715 C-Type 0.015007
GSM1448211 SNU977 Stem 0.000990 C4 0.001006 Subtype D 0.003252 CCS3 0.116734 C-Type 0.014506
GSM1448102 COGA8 Stem 0.001267 C1 0.001235 Subtype D 0.011042 CCS3 0.048430 C-Type 0.029072
GSM1448173 COLO320DM Stem 0.001267 C4 0.000751 Subtype D 0.001510 CCS3 0.005134 C-Type 0.291489
GSM1448144 NCIH716 Stem 0.001973 C4 0.005337 Subtype D 0.002157 CCS3 0.113874 C-Type 0.158788
GSM1448152 COLO320 Stem 0.002293 C4 0.000751 Subtype D 0.001776 CCS3 0.014727 C-Type 0.051607
GSM1448125 HCA7 Stem 0.002593 C2 0.000751 Subtype D 0.022645 CCS2 0.032419 C-Type 0.011612
GSM1448148 CL11 Stem 0.006247 C4 0.000729 Subtype D 0.007686 CCS3 0.032419 C-Type 0.038077
GSM1448104 HDC8 Stem 0.015689 C4 0.001006 Subtype C 0.132201 CCS3 0.270032 A-Type 0.159419
GSM1448093 HROC80 Stem 0.042435 C2 0.024357 Subtype C 0.023968 CCS3 0.462838 A-Type 0.204528
GSM1448162 HCT8 Stem 0.069052 C4 0.003407 Subtype D 0.011535 CCS2 0.189027 C-Type 0.003659
GSM1448182 COLO320HSR Stem 0.072001 C4 0.000751 Subtype D 0.004473 CCS3 0.017030 C-Type 0.074093
GSM1448192 SNU1544 Stem 0.080769 C2 0.001235 Subtype D 0.301940 CCS2 0.301107 A-Type 0.164496
GSM1448092 HCT116 Stem 0.162033 C4 0.005162 Subtype D 0.067002 CCS3 0.115157 C-Type 0.004645
GSM1448161 DLD1 Stem 0.311486 C4 0.072692 Subtype D 0.445976 CCS3 0.138248 C-Type 0.450929
GSM1448126 LIM2405 Stem 0.370679 C2 0.001235 Subtype D 0.051330 CCS2 0.189831 C-Type 0.068408
Gene/Exon
KRAS EX2 FORW GGTGGAGTATTTGATAGTGTATTAACC
KRAS EX2 REV AGAATGGTCCTGCACCAGTAA
KRAS EX2 SEQ FOR TCATTATTTTTATTATAAGGCCTGCTG
KRAS EX3 FORW AAAGGTGCACTGTAATAATCCAGAC
KRAS EX3 REV ATGCATGGCATTAGCAAAGA
KRAS EX3 SEQ FOR CCAGACTGTGTTTCTCCCTTC
KRAS EX4 FORW + SEQ TGGACAGGTTTTGAAAGATATTTG
KRAS EX4 REV ATTAAGAAGCAATGCCCTCTCAAG
NRAS exon2 FORW + SEQ GTACTGTAGATGTGGCTCGC
NRAS exon2 REV AGAGACAGGATCAGGTCAGC
NRAS exon3 FOR CTTATTTAACCTTGGCAATAGCA
NRAS exon3 REV + SEQ GATTCAGAACACAAAGATCATCC
HRAS exon2 FORW GGCAGGAGACCCTGTAGGA
HRAS exon2 REV + SEQ AGCCCTATCCTGGCTGTGT
HRAS exon3 FORW + SEQ AGAGGCTGGCTGTGTGAACT
HRAS exon3 REV ATGCGCAGAGAGGACAGGA
BRAF ex15 FORW TGCTTGCTCTGATAGGAAAATG
BRAF ex15 REV AGCATCTCAGGGCCAAAAAT
BRAF ex15 SEQ FOR TGTTTTCCTTTACTTACTACACCTCA
PIK3CA  EX9 FORW GGGAAAAATATGACAAAGAAAGC
PIK3CA  EX9 REV CTGCTTTATTTATTCCAATAGGTATGG
PIK3CA  EX9 SEQ FOR TAGCTAGAGACAATGAATTAAGGGAAA
PIK3CA  EX20 FORW CTCAATGATGCTTGGCTCTG
PIK3CA  EX20 REV TGGAATCCAGAGTGAGCTTTC
PIK3CA  EX20 SEQ FOR TTGATGACATTGCATACATTCG
Primers (5'-> 3')
Supplementary Data 3. Sanger sequencing primers's sequencees.                                                                        
Table lists primers used to sequence 16 hot spot mutations in KRAS, NRAS, HRAS, 
BRAF and PIK3CA. 
siRNA Target siRna Sequence (5'->3')
ALK GACAAGAUCCUGCAGAAUA
ALK GGAAGAGUCUGGCAGUUGA
ALK GCACGUGGCUCGGGACAUU
ALK GGUCAUAGCUCCUUGGAAU
FGFR2 CCAAAUCUCUCAACCAGAA
FGFR2 GAACAGUAUUCACCUAGUU
FGFR2 GGCCAACACUGUCAAGUUU
FGFR2 GUGAAGAUGUUGAAAGAUG
KIT AAACACGGCUUAAGCAAUU
KIT GAACAGAACCUUCACUGAU
KIT GGGAAGCCCUCAUGUCUGA
KIT GCAAUUCCAUUUAUGUGUU
NTRK1 GGACAACCCUUUCGAGUUC
NTRK1 CCAGUGACCUCAACAGGAA
NTRK1 CCACAAUACUUCAGUGAUG
NTRK1 GAAGAGUGGUCUCCGUUUC
NTRK2 GAACAGAAGUAAUGAAAUC
NTRK2 GUAAUGCUGUUUCUGCUUA
NTRK2 GCAAGACACUCCAAGUUUG
NTRK2 GAAAGUCUAUCACAUUAUC
PDGFRA CAUCAGAGCUGGAUCUAGA
PDGFRA GGCCUUACUUUAUUGGAUU
PDGFRA GAGCUUCACCUAUCAAGUU
PDGFRA CCUCUAGGAAUGACGGAUU
RET GCAAAGACCUGGAGAAGAU
RET GCACACGGCUGCAUGAGAA
RET UUAAAUGGAUGGCAAUUGA
RET GCGAGGAGAUGUACCGCCU
Supplementary Data 4. siRNA sequencees.                                                                        
For each target gene a pool of 4 siRNA was used. The table lists the 
sequencees of each siRNA included in the corresponding pool.
